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Zusammenfassung 
Eosinophilia in children with endemic Burkitt lymphoma in Malawi as a prognostic 
factor for survival 
Schlau, Hannah Naomi 
Das endemische Burkitt Lymphom ist die häufigste pädiatrische Krebserkrankung in 
Zentralafrika. Angesichts knapper Ressourcen vor Ort besteht dringender Bedarf an 
optimierten Therapien, welche durch eine erweiterte Risikostratifizierung erreicht 
werden könnten. In dieser Arbeit wurde gezielt die Fragestellung untersucht, ob 
Eosinophilie bei Diagnosestellung einen Risikofaktor darstellt.  
In diese retrospektive Studie mit 12 monatigem Follow-up wurden 479 pädiatrische 
endemische Burkitt Lymphom Fälle aus der Zeit zwischen 1997 und 2009 in Malawi 
eingeschlossen. Mittels Literaturrecherche und univariater Analyse identifizierte 
Variablen wurden in ein Intervall-zensiertes lineares Modell integriert, um unabhängige 
Einflussvariablen auf das Überleben zu erfassen. 
Das mediane Alter lag bei 7.0 Jahre (M:F Ratio 1.8:1, Stadium I 69 (14.4%), II 107 (22.3%), 
III 224 (46.8%) und IV 73 (15.2%) Patienten). Der mediane Eosinophilen-Wert betrug 0.10 
x 10³/µl (Bereich: 0.00 -9.50 x 10³/µl). 122 Kinder (25.5%) präsentierten eine Eosinophilie. 
Innerhalb der 12 Monate erlitten 174 Patienten (36.3%) ein Rezidiv oder Tod, 77 (16.1%) 
blieben Tumor frei. Die multivariate Analyse ergab, dass Patienten mit Stadien III, IV ein 
signifikant erhöhtes Risiko für ein Ereignis haben (chi² 0.019, exp(B) 1.579 [1.082-2.359]). 
Eosinophilie hatte keinen signifikanten Einfluss auf das ereignisfreie Überleben, allerdings 
bestand ein Trend für die Assoziation von Eosinophilie mit einem erniedrigten Risiko für 
ein Ereignis (chi² 0.215, exp(B) 0.777 [0.521-1.158]).  
Zusammenfassend spielt Eosinophilie im multivariaten Analysemodell keine signifikante 
Rolle für das Überleben von Kindern mit endemischem Burkitt Lymphom.                
Tag der mündlichen Prüfung: 25.02.2014 
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1 INTRODUCTION 
1.1 Malawi 
We studied endemic Burkitt Lymphoma (eBL) in Malawi, a country with one of the 
highest incidences of this disease. Malawi is located in the Southeast of Africa with no 
access to the Indian Ocean. Lake Malawi is Africa’s third largest lake.(130) To the 
North, Malawi borders on Tanzania, to the West on Zambia, and to the East on 
Mozambique. While Lilongwe is Malawi’s capital, Blantyre in the South is the largest 
city. In 2010, Malawi’s total population comprised 14,901,000 people.(139,129) In the 
same year, average life expectancy at birth was 44 years for males and 51 years for 
females.(139) In 2004, 73.9% of the population was living on less than $ 1 (PPP 
International (Intl.) $) a day.(140) In 2010, the total expenditure on health per capita 
added up to a mean of 50 Intl. $ in Malawi.(139) In comparison, the mean total 
expenditure on health per capita in Germany was 4,129 Intl. $ in 2009.(141) Malawi 
ranked 26th in the under-5-mortality rate chart of 2009 by UNICEF.(129) The under-5-
mortality rate expresses the “probability of a child born in a specific year or period 
dying before reaching the age of five, if subject to age-specific mortality rates of that 
period”.(147) 
1.2 Cancer in Malawi & Sub-Saharan Africa 
“The WHO global burden of disease (GBD) measures burden of disease using the 
disability-adjusted life year (DALY). This time-based measure combines years of life lost 
due to premature mortality and years of life lost due to time lived in states of less than 
full health. The DALY metric was developed in the original GBD 1990 study to assess the 
burden of disease consistently across diseases, risk factors and regions.”(142) 
As a study on disease burden in Malawi in 2002 by WHO revealed, young children have 
the greatest mortality among Malawi’s total population and carry the largest burden of 
disease.(16)  
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Main causes of burden of disease in Malawi are HIV/AIDS, lower respiratory tract 
diseases, malaria and diarrhoeal diseases.(16) Thus, infectious disease has the most 
relevant role in burden of disease and represents the most important cause of 
death.(16,78) Cancer has up to now been a minor cause of deaths in both childhood 
and adulthood in Malawi and Africa.(16,78) However, there is strong evidence that the 
incidence of both cancer in general and Non-Hodgkin Lymphoma (NHL) increases in 
Sub-Saharan countries.(135) To our knowledge, there is no exact data about the actual 
incidence and prevalence of childhood cancer in Malawi. However, an estimate by 
Israels et al. led to the assumption of 900 new cancer cases in children younger than 
15 years every year.(57,123)   
The paediatric oncology ward “Sobo ward” at Queen Elizabeth Central Hospital (QECH) 
in Blanytre, Malawi, was founded in 1997.(57) It offers 17 beds for children with 
cancer.(57) Five nurses, 1 social worker, 1 play lady and 1 clinical officer as well as an 
attending paediatrician take care of the patients.(57) Patients are mainly from the 
Southern part of Malawi but also come from Northern parts or even Mozambique.(57) 
Every year about 160 children are admitted to this oncology ward.(57) The three major 
cancers are eBL, Wilms tumor and HIV-associated Kaposi sarcoma.(57) 
In general, the cancer care system for children in Sub-Saharan Africa is very limited, as 
other problems such as infectious disease and malnutrition are more predominant and 
adequate resources are lacking.(59,78,101) Improvements in childhood cancer care in 
low-income countries are urgently required.(83,101) 
1.3 Burkitt Lymphoma 
Denis P. Burkitt, a British surgeon, first described Burkitt lymphoma (BL) in 1958 as a 
sarcoma involving the jaws in African children on the basis of his working experience at 
Mulago Hospital, Kampala, Uganda.(21)  
In his first publication, Burkitt had already noted that BL constituted the largest share 
of paediatric tumour diseases at Mulago hospital, Uganda.(21) Ever since, 
epidemiology studies have shown malignant lymphoma and especially BL to be the 
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most common types of paediatric tumour diseases across the tropical belt in 
Africa.(5,47,137) In a review of the histologies of about 600 fine needle aspirates of 
lymphoma in children <18 years of age from Sub-Saharan Africa, BL accounted for 
more than 80% of all NHL.(89) Based on these findings, Naresh et al. estimated the 
incidence of BL in equatorial African countries to be 30-70 per million children.(89) 
Between 1994 and 1998, BL represented more than 40% of childhood cancers at QECH 
in Blantyre Malawi.(11) In overall Malawi, more than 50% of childhood cancers are 
BL.(45 cit. a. 50) In Uganda, similar numbers were found.(30 cit. a. 5) However, 
childhood cancer is not a health priority in most developing countries and assessment 
of its incidence and prevalence is difficult due to the resulting underreporting.(5) 
BL belongs to the rapidly proliferating B-cell NHL.(70) In fact, it is one of the fastest 
growing human cancer entities with doubling times below 72h.(60,148) It is classified 
into three categories: sporadic BL (sBL), occurring throughout the world, endemic BL 
(eBL), predominantly located in the high-prevalence malaria areas of Sub-Saharan 
Africa and Papua New Guinea, and AIDS-associated BL.(70) Endemic and sporadic BL 
do not only differ in geographic terms but also in manifestation sites, pathogenesis, 
and in incidence.(70) Despite research efforts, the pathogenesis of BL is to date not 
fully understood.  
Studies have found a close to 100% association of eBL with Ebstein-Barr virus (EBV) 
(84,102,153) while sBL is associated with EBV in approximate 30% of cases (70). 
Remarkably, eBL occurring within the African equatorial belt is strongly aligned with 
heavy rainfall and high temperature areas while it rarely occurs in high-altitude 
regions.(120) Due to this geographic congruence of eBL and endemic malaria area, 
plasmodium falciparum is thought to play a crucial role in lymphomagenesis.(31 cit a. 
76;34,88) However, as malaria and EBV infection do not sufficiently explain the 
pathogenesis of eBL, additional cofactors like arbovirus infection and contact with 
specific plants have been discussed.(39,132) Moreover, schistosomiasis and 
socioeconomic factors such as family environment have been considered as possible 
surrogate risk factors for the previously mentioned factors.(108,6) 
4 
 
Beside the specific sub-type of BL associated with AIDS, it has been discussed whether 
HIV-infection also plays a role in the pathogenesis of eBL.(50,88,102)  
The molecular pathogenesis of BL is based on a reciprocal translocation involving 
chromosome 8 and chromosome 14 or chromosome 2 or 22 (26,82,150), resulting in 
aberrant expression of the oncogene c-myc. 
In comparison to sBL, in which paediatric patients mostly present with abdominal 
manifestations, eBL mainly affects the facial area (maxillary and mandibular bones), 
followed by abdominal involvement and cerebral involvement.(70,104,120) 
Furthermore, paraplegia or incontinence can be caused by BL.(70,104) In Uganda, BL is 
in fact the most frequent cause of these symptoms.(70,104,120) 
In developed countries, long-time survival rates in sBL have tremendously improved 
over the past decades reaching a 4-year event free survival (EFS) of up to 98% in 
limited disease and 5-year EFS of up to 85% for all stages.(20,22,23,38) Even though 
therapy and outcome have also highly progressed in developing countries, adverse 
local conditions do not allow for comparable success rates.(44,47-50,65,86,92,93,128) 
In one of the most recent treatment studies applying a risk adapted therapy in 
Cameroon, a 1-year EFS of 61% was achieved.(49)  
A huge problem concerning the therapy of eBL and other lymphomas in developing 
countries is the drug toxicity which is associated with a high rate of treatment-related 
mortality.(47,50,138) As demonstrated in the study in Cameroon by Hesseling, risk 
adapted treatment has the potential to improve EFS by balancing intensity of 
treatment and toxicity.(49) For this reason, risk stratification is essential to optimize 
therapy. 
To date, there are only few accepted and established risk factors for the outcome of 
eBL as there have not been many studies on this subject. Stage (limited vs extensive 
disease), localisation, age, bone marrow (BM) and central nervous system (CNS) 
involvement, serum total lactate dehydrogenase (LDH), serum creatinine, early antigen 
of EBV (anti-EA) and uric acid have been shown to be relevant prognostic/risk factors 
in at least one study.(8,74,86,92,96,98) In sBL staging, LDH and BM and CNS 
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involvement are recognised as prognostic factors.(19,23) In this work, we have 
addressed a potential role of eosinophilia as a prognostic factor in eBL. 
1.4 Eosinophilia  
Eosinophilia is categorized as haematological primary (clonal) (10,29) and non-
haematological secondary (reactive) eosinophilia (28). A further classification 
differentiates hypereosinophilic syndrome defined as >1.5 x10³/µl, absence of 
common cause of eosinophilia and organ damage (27,40) and eosinophilia due to 
other reasons as mentioned above. If clonal and secondary causes are ruled out, a 
diagnosis of idiopathic eosinophilia or hypereosinophilic syndrome may be 
justified.(110) There are various causes for secondary eosinophilia.(99) In developed 
countries, asthma is one of the most common causes (99,124), and this association 
was also shown in developing countries (136). Eosinophilia can further be found in 
certain rheumatologic diseases, allergic drug reactions, eosinophilic pneumonia, 
neoplastic diseases, Churg-Strauss-syndromes, and infections.(64,113) It is also a 
pathophysiological reaction of the human immune system to various tissue-invasive 
parasites as hookworm infection (80), schistosomiasis (17,36), trichinellosis (106) and 
others.(118) The major causes of eosinophilia in developing countries are parasitic 
infections.(51,53,105) Our hypothesis that eosinophils may be involved in the 
pathogenesis and course of disease in eBL was raised by observations that eosinophils 
can have toxic effects on tumour cells.(43,54) Moreover, associations of eosinophilia 
with certain haematological malignancies including Hodgkin’s disease (114), acute 
lymphoblastic leukemia (ALL) (9,52,81), and T-cell NHL (73), but also with solid 
tumours such as thyroid cancer (131) or cervical cancer (109,132,149) have been 
reported.  
We did not find any publication dealing with the impact of eosinophilia on the 
outcome in paediatric NHL. However, there was one study conducted in India 
addressing the subject of predictive value of eosinophilia for outcome in childhood 
acute myeloid leukaemia (AML).(3) 
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1.5 Hypothesis & Objective 
This study is based on observations reported by responsible paediatricians at Sobo 
ward that many BL patients had elevated eosinophilic blood counts at diagnosis, and 
that these patients tended to have better survivals. We, therefore, decided to conduct 
a retrospective study to substantiate these observations. As mentioned above, there 
have not yet been any studies on the role and relevance of eosinophilia in eBL nor any 
of the two other BL subtypes. 
As outlined in the previous chapter, eosinophils play an important role in the immune 
response. However, their functions and role in human disease, especially in cancer, are 
not fully understood. Excessive increase of blood eosinophils can cause serious 
damage to organs and tissues.(27,40) Eosinophils have also been shown to contribute 
to cytotoxic effects on tumor cells.(43,54) These finding support the reported possible 
association of eosinophilia and outcome observed at QECH in Blantyre Malawi.     
The hypothesis of this dissertation is that eosinophilia in patients with endemic Burkitt 
lymphoma is a positive prognostic factor for EFS within 12 months period after 
discharge from hospital. The objective is to identify a prognostic factor that is feasible 
to assess with limited resources and that can be clinically used in patients with eBL in 
Malawi and other low-income countries in order to differentiate between low and high 
risk patients and adjust treatment intensity.  
2 METHOD AND MATERIALS 
2.1 Study design 
The study design was a retrospective cohort analysis comparing eBL patients with 
event to those patients without event during the 12 month control period after 
completion of first line chemotherapy according to protocol and discharge.  
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2.2 Data acquisition 
As a retrospective study, data was collected from pre-existing documentation of all 
patients with endemic Burkitt lymphoma exclusively treated at the oncological Sobo 
ward of QECH, Blantyre, Malawi between 1997 and June 2009. The data collection 
took place in August and September of 2009.   
When patients were admitted to Sobo ward and diagnosis of eBL was confirmed, a 
folder was initiated in which all relevant medical information was documented. After 
completing therapy protocol and follow-up, these folders were archived at QECH.  
Besides general information about the patient and her or his history and regular notes 
concerning clinical status, results of examinations (sonography, bone marrow 
puncture, cerebrospinal fluid), laboratory analyses and histopathologic exploration, 
treatment protocols, schedules and assessment of toxicity effects were included into 
this documentation. Furthermore, the patient’s status at the four time points of 
restaging and follow-up was documented.  
Every case with a diagnosis of ‘eBL’ and who was treated according to the respective 
treatment protocol was included into the study without exception. Data concerning 
the following characteristics at diagnosis were summarized in an Excel® sheet: Age, 
sex, stage of disease, localisation of tumour, central nervous system (CNS) 
involvement, bone marrow (BM) involvement, human immunodeficiency virus (HIV) 
status, the following blood parameters: complete blood count, absolute neutrophil 
count, absolute eosinophil count, relative eosinophil count, absolute lymphocyte 
count, relative lymphocyte count, and absolute monocyte count; malaria infection, 
parasites in stools, parasites in urine, therapy protocol. Follow-up assessment included 
outcome at discharge, outcome at 1 month after discharge, outcome at 6 months after 
discharge and outcome at 12 months after discharge.  
2.3 Diagnosis and testing methods 
Diagnosis was based on clinical examination and sonography, both performed by the 
responsible doctor or medical officer of Sobo ward. Further, tumour fine needle 
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aspiration was performed, and histopathologic examinations of the aspirates were 
performed by Professor Liomba in his private practice and laboratory in Blantyre. 
Moreover, cerebral spinal fluid (CSF) puncture and a bone marrow aspiration mostly at 
the posterior iliac crest were conducted in the majority but not in all patients. 
Cytomorphologic analysis of CSF cytospins and BM aspirates were also performed by 
Professor Liomba. Staging was performed according to the St.Jude (Murphy’s) 
Classification (see Table 2.1).  
 
Initial testing also included HIV testing by rapid tests at the VCT clinic (voluntary 
counselling and testing) if patients were older than 18 months. Moreover, malaria 
testing was conducted by the Malawi Liverpool Wellcome Research Laboratories at 
QECH. Testing for parasites in both stools and urine was carried out in the paediatric 
department of the College of Medicine at QECH. Full blood counts were done using a 
Table 2.1 St. Jude (Murphy’s) Classification (87) for Childhood Non-Hodgkin lymphoma 
Stage Description 
I A single (extranodal) or single anatomic area (nodal), with the exclusion of mediastinum or 
abdomen 
II A single tumour (extranodal) with regional node involvement 
Two or more nodal areas on the same side of the diaphragm 
Two single (extranodal) tumours with or without regional node involvement on the same 
side of diaphragm 
A primary gastrointestinal tract tumour, usually in the ileocecal area, with or without 
involvement of associated mesenteric nodes only, which must be grossly (>90%) resected 
III Two single tumours (extranodal) on opposite sides of the diaphragm 
Two or more nodal areas on both sides of the diaphragm 
Any primary intrathoracic tumour (mediastinal, pleuric, or thymic) 
Any extensive primary intra-abdominal disease 
IV Any of the above, with initial involvement of central nervous system or bone marrow at the 
time of diagnosis 
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coulter counter and were performed by the Malawi-Liverpool Wellcome Trust Clinical 
Research Centre in Blantyre.  
Follow-up visits in order to assess patients’ tumour status after discharge were 
supposed to take place at 1, 6, and 12 months after diagnosis in case of no complaints. 
Patients received follow-up appointments at discharge. If signs of tumour relapse were 
present, immediate reassessment was recommended. If patients failed to show up for 
their follow-up appointments, staff of Sobo ward (doctors and nurses) attempted to 
visit the patients at their homes if resources were available. In some cases, they 
succeeded in finding the patients and assessing their health status, in others they did 
not. 
Tumour status or occurrence of events as relapse or death was assessed at follow-up 
appointments by anamnesis, clinical and sometimes laboratory findings. In case of 
death, the cause could not be identified from the records most of the times. 
2.4 Definitions and data management 
Definition of eosinophilia is critical since it represents the major aspect of this work:  
Eosinophilia was defined as any value exceeding the common reference values for 
children (see Table 2.2, page 10).(66) During extensive literature research on 
eosinophilia in children and its definition, we found that the data and publications 
concerning this subject were inconsistent. Some research groups and researchers 
defined eosinophilia as values above 0.5 cells x10³/µl (64), others as 0.35 cells x10³/µl 
(112), 0.45 cells x10³/µl (66,118), or 0.65 cells x10³/µl (113). As mentioned, we decided 
to define eosinophilia as any value above standard reference range because we found 
it to be most reasonable in the context of this study.  
We are aware that standard reference values for blood parameters may be inadequate 
to represent the paediatric population in Malawi. There have been some approaches 
to establish African or even East-African reference values for children.(18,55) Since 
these work-studies have only been first steps towards independent reference values 
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and well-established haematological reference values for children in Malawi, in this 
work standard western reference values are used.  
Nathan’s and Oski’s Hematology of Infancy and Childhood is one of the most widely 
used standard textbooks for haematological and oncological diseases in paediatrics. 
Unfortunately, reference values given in this textbook are not comprehensive, 
particularly, reference ranges for differential white blood cell parameters as 
eosinophils are lacking.(99) For this reason, Nathan´s and Oskin´s is an inadequate 
reference for this work.  
German standard literature 
provides detailed age-
categorized reference values 
for white blood cell 
parameters.(69) However, 
German references do not 
seem appropriate for this 
Malawi-concerned work as 
Germany’s population has 
very small shares of people 
with African 
background.(122)  
A widely used, prestigious 
international standard 
reference textbook in 
paediatrics is the Nelson’s 
Textbook of Pediatrics. We 
decided to use the partially 
age-adjusted reference 
values for blood parameters 
from Nelson’s Textbook.(66)  
Table 2.2 Reference values Differential Blood (66)  
Haemoglobine (g/dl) 1-23 months 10.5-14.0 
2-9 years 11.5-14.5 
10-17 years 
male 
12.5-16.1 
10-17 years 
female 
12.0-15.0 
White blood cells 
(x10³/µl) 
1-23 months 6.0-14.0 
2-9 years 4.0-12-0 
10-17 years 4.0-10.5 
Neutrophils (seg) 
(x10³/µl) 
3.0-5.8 
Neutrophils (seg) % 54-62 
Lymphocytes (x10³/µl) 1.5-3.0 
Lymphocytes % 25-33 
Monocytes (x10³/µl) 0.285-0.5 
Monocytes % 3-7 
Eosinophils (x10³/µl) 0.05-0.25 
Eosinophils % 1-3 
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Outcome was defined as EFS within the 12 months control period. Events were relapse 
or death. Once patients had experienced relapse, they were dealt with as an event 
throughout the rest of the study period regardless whether they were rescued by 
relapse therapy or not.  
This means that overall survival was not assessed. Reasons for not addressing overall 
survival were on the one hand the lack of sufficient data about relapse schedules and 
on the other hand the fact that EFS at 1 year is thought to be an adequate indicator for 
overall survival in eBL. In case of EFS at 1 year, long-term survival becomes highly 
likely.(48,83,93) In case a patient was not seen 1 month after discharge but after 6 
months being in a tumour-free condition, tumour-free status was assumed for the 
prior control date since spontaneous recovery is highly unlikely in BL. Some patients 
were not seen after the first control date, thus information about their tumour status 
for 6 and 12 months’ time is missing. 
Outcome / EFS was predominantly managed as a dependent variable throughout the 
statistical analyses.  
All aspects of data management and statistical data analysis and illustrations of results 
were conducted with the statistics program IBM SPSS Statistics 19®. 
The following parameters were integrated into SPSS as variables: Age (continuous), sex 
(nominal), HIV-status (nominal), stage of disease (ordinal), localisation of tumour 
(nominal), CNS involvement (nominal), presence of paraplegia/ incontinence (nominal), 
bone marrow involvement (nominal), therapy protocol (nominal), haemoglobin 
(continuous), leukocytes (continuous), absolute neutrophil count (continuous), 
absolute eosinophil count (continuous), relative eosinophil count (continuous), 
absolute monocyte count (continuous ), absolute lymphocyte count (continuous), 
relative lymphocyte count (continuous), malaria (nominal), parasites in stools 
(nominal), parasites in urine (nominal), outcome at control date discharge, 1 month, 6, 
and 12 months (ordinal).  
For statistical purposes, most continuous variables were recoded into additional 
categorical variables. Hence, age was transferred into a nominal variable with 4 
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subgroups classification of age. The continuous blood parameters were classified into 
reduced, normal or elevated ranges defined on the basis of partly age-related 
reference values given by globally accepted standard literature in paediatrics.(66)  
The following ordinal variables were created: classification of leukocyte count, 
classification of absolute neutrophil count, classification of absolute eosinophil count, 
classification of relative eosinophil count, classification of absolute lymphocyte count, 
classification of relative lymphocyte count and classification of absolute monocyte 
count.   
These newly created variables and some of the other categorical variables with more 
than two categories were additionally transferred into binary variables to allow cross 
tabulations and risk analysis. Thus, the variable set was complemented by the 
following binary variables: STAGE A comparing stages I and II to stages III and IV, STAGE 
B comparing stages I to III with stage IV, localisation A contrasting exclusive facial and 
sole abdominal localisations, localisation B dividing localisation into no abdominal and 
any abdominal masses, paraplegia, anaemia, leukopenia, leucocytosis, absolute 
neutropenia, absolute neutrophilia, absolute eosinopenia, absolute eosinophilia, 
absolute lymphopenia, absolute lymphocytosis, relative lymphopenia, relative 
lymphocytosis and absolute monocytosis. 
With regard to the assessment of tumour status at the four control points, it needs to 
be considered that some of the patients could not be followed up according to the 
planned schedule. Thus, in some study cases, information about their status at some of 
the control time-points is lacking.  
2.5 Statistical data analysis 
First, the study population was generally described by frequencies and means 
concerning diverse parameters. Complementary diagrams for visualization were 
generated. 
Second, cross tabulation calculations were performed on outcome at each time point 
and on various variables including eosinophilia in order to identify simple significant 
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correlations. Significance was calculated by Fischer-Yates-Test and was yet defined as 
chi-square < 0.05.  
In addition to the statistical analysis, further factors which might influence the 
outcome were identified through comprehensive literature research. After appropriate 
dataset preparations, these statistically and theoretically defined parameters where 
included into a generalized linear model to assess significantly influencing parameters 
and to describe their effects on the probability of event-free survival after 12 months. 
Generalized linear model was performed by designing an interval-censored log log 
regression according to Wald.  
As type of model, interval censored survival was chosen. Outcome was defined as the 
dependent variable. The identified factors which potentially affect outcome were 
defined as predictors. Since all of them were categorical variables, they were 
integrated as factors not as covariates. In the case of missing values, cases were 
excluded. For parameter estimation, the Fisher method was chosen. Further, the 
Pearson chi-square was selected as Scale parameter method. In the tab Statistics, 
analysis type Type III was chosen since it is applicable for all types of analysis.  
Significance was again defined as chi-square < 0.05. The odds ratio is equivalent to 
Exp(B) statistically describing the probability of event given specific factors.  
3 RESULTS 
3.1 Characterization of the patient population 
3.1.1 General numbers 
Overall, a total of 479 patients were included into the retrospective study. The 
patients’ age ranged from 1 to 18 years (median: 7.00 years). More than 50% of the 
study population was between 5 and 9 years old (Diagram 3.1, page 14). 
35.3% (169) of the patients were female, 64.1% (307) were male. In 3 cases (0.6%), no 
data about the sex was found. The M:F ratio equals 1.8:1.  
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Diagram 3.1 Age distribution (frequencies)  
 
 
3.1.2 Stage of disease  
Sixty-nine patients (14.4%) were diagnosed as Stage I, 107 (22.3%) were Stage II, 224 
(46.8%) Stage III, and 73 patients (15.2) had Stage IV disease. There were six undefined 
cases (1.3%).  
Diagram 3.2 (page 15) shows the distribution of disease stages for all patients.    
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Diagram 3.2 Stage distribution (percent)  
 
 
 
3.1.3 Localisation of tumour 
All patients were examined with respect to localisation site/s of the tumour. Four 
different localisation site groups were defined: facial, abdominal, facial & abdominal 
and other manifestation sites (as arm, knee, shoulder, and spine).  
Two-hundred thirty-two (48.4%) of the patients had an exclusive manifestation in the 
facial area, 131 of the patients (27.3%) had an isolated manifestation in the abdomen, 
whereas 96 patients (20.0%) had a combined manifestation of both face and abdomen. 
The 19 remaining patients (4.0%) presented with other, more uncommon 
manifestation sites of the tumour (Diagram 3.3, page 16). Only in one case (0.2%), the 
tumour site was not evident from the files.  
Localization A showed 232 patients with facial involvement only vs. 131 patients with 
exclusive abdominal involvement. Localization B focusing on the abdominal 
manifestation site revealed 251 patients to be without any abdominal tumours and 
227 patients to have any abdominal involvement. 
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Diagram 3.3 Tumour localisation at presentation (percent) 
 
 
 
 
3.1.4 CNS involvement  
The patient population was examined with regard to cerebral involvement of Burkitt 
lymphoma cells by cytomorphologic examination of spinal fluid.  
Four-hundred twenty-nine patients (89.6%) did not show a cerebral involvement 
whereas 38 children (7.9%) presented with CNS manifestation. In 12 cases (2.5%), the 
documentation did not provide information about a potential involvement of the CNS.  
3.1.5 Paraplegia 
In case tumour cells infiltrate the spinal cord, paraplegia, incontinence or both may 
result.(151) For this reason, the presence of paraplegia and/or urinary incontinence 
symptoms in patients was documented.  
17 
 
Thirteen patients (2.7%) presented with isolated paraplegia whereas 18 patients (3.8%) 
presented with both paraplegia and incontinence. 5 patients (1.0%) showed an 
isolated incontinence.   
Eight patients with paraplegia and/or incontinence also presented a CSF aspirate with 
Burkitt lymphoma cells.   
3.1.6 Bone marrow involvement 
Bone marrow involvement was assessed in bone marrow aspirates.  
According to the files, in 395 cases (82.5%) the bone marrow did not contain 
lymphoma cells. 32 patients (6.7%) presented with bone marrow involvement. In 52 
cases (10.9%) there was no documentation about a bone marrow involvement.  
3.1.7 HIV status  
Twenty-three patients (4.8%) were HIV-positive whereas 442 patients (92.3%) were  
 
Diagram 3.4 HIV status (percent)  
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tested HIV-negative (Diagram 3.4, page 17). In 14 cases, there was no testing done or 
documented. 
3.1.8 Blood counts 
On admission, complete peripheral blood counts were done in every patient. Of special 
interest for the present study were the results of the haemoglobin as well as the white 
blood cell counts and their differentiation.  
Age-adjusted reference values of the Nelson´s Textbook of Pediatrics were used for 
comparison (Table 2.2, page 10). 
 
One-hundred and two patients (21.3%) had normal haemoglobin concentration 
(median 10.30 g/dl [range: 3.10 to 15.40 g/dl]).  
 
Diagram 3.5 Haemoglobin distribution (histogram) 
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In 373 cases (77.9%), patients presented with reduced haemoglobin levels with regard 
to their age-group (Diagram 3.5, page 18). Three patients showed elevated 
haemoglobin levels (0.6%). In one case, the haemoglobin level was not documented. 
Severe anaemia was defined as haemoglobin levels below 5.0 g/dl.(24) It was found in 
9 cases (1.9%). 
Three-hundred fifty-eight patients (79.3%) had a normal WBC count according to their 
age (Diagram 3.6, below). Median WBC count was 8.50 x 10³/µl (range: 1.70 to 57.40 x 
10³/µl). Thirty-eight children (7.9%) had leukopenic cell counts, and 83 patients 
(17.3%) presented with an elevated number of leukocytes. 
 
Diagram 3.6 White blood cells (histogram)  
 
 
Regarding neutrophilic counts, 222 cases (46.3%) showed values within the normal 
range. The median value was 3.64 x10³/µl (range: 0.20 to 8.30 x10³/µl). 174 patients 
(36.3.%) presented with neutropenia whereas 80 patients (16.7%) with neutrophilia. In 
3 cases, no neutrophilic values were documented. 
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Lymphocytes were within the normal range in 158 cases (33.0%), with a median of 
3.40 x10³/µl and levels ranging from 0.60 to 10.00 x10³/µl. Forty patients (8.4%) 
presented with lymphopenia whereas 278 cases (58.0%) showed elevated lymphocytic 
counts. Documentation about the lymphocytic count was lacking in 3 cases.  
Relative lymphocytic counts were within the normal range in 74 cases (15.4%). 45 
cases had a reduced relative lymphocytic count (9.4%) while 359 patients presented 
with relative lymphocytosis (74.9%).  
With regard to eosinophils, the median was 0.10 x 10³/µl with levels ranging from 0.00 
to 9.50 x 10³/µl (Diagram 3.7, below). According to the reference values, 147 patients 
(30.7%) presented with a normal eosinophilic count whereas 122 children (25.5%) 
presented with elevated eosinophils. Most of the patients (185 patients, 38.6%) 
presented with absolute eosinopenia (Diagram 3.8, page 21). 
 
Diagram 3.7 Absolute eosinophils (histogram) 
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Two-hundred thirty-one patients (48.2%) had relative eosinophilic levels below 
reference range, 103 patients (21.5%) within the range, and 115 patients (24.0%) had 
elevated levels.  
The median value of monocytes was 0.60 x 10³/µl with levels ranging from 0.00-8.50 
x10³/µl. The evaluation of absolute numbers of monocytes showed in 137 cases 
(28.6%) a count within the normal range. Two-hundred sixty-six patients (55.5%) 
presented with elevated levels of monocytes whereas 54 (11.3%) patients presented 
with reduced monocytic counts. In 22 cases, there was no documentation about the 
monocytic count.  
Two-hundred patients (41.8%) presented with normal relative monocytic counts. 23 
(4.8%) had levels below the reference range and 237 patients (49.5%) above it.   
 
Diagram 3.8 Classification Absolute Eosinophils (percent) 
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3.1.9 Parasitic infections 
Concerning parasitic infections, the children were tested for malaria as well as for 
bowel and urinary tract parasites.  
Four-hundred twenty-five patients (88.7%) presented with a plasmodium negative 
blood smear. Forty-four patients (9.2%) presented with a current malaria infection. In 
10 cases there was no documentation concerning malaria testing.   
On examination of the stools, 421 patients (87.9%) of the patients did not show signs 
of a parasitic bowel infection, whereas 27 (5.6%) showed, in order of frequency, signs 
of hookworms and ova (17), strongyloides stercorales (worms, ova) (7), gardia lamblia 
(1), schistosomiasis mansoni (1) and taenia ova (1) infections. In 31 cases (6.5%), no 
documentation about parasitic infection was found.  
The examination of the urine revealed an infection with schistosomiasis haematobium 
in 50 cases (10.4%), while 399 patients (83.3%) did not present with a parasitic urinary 
tract infection. In 30 cases (6.3%), there was no data.  
3.1.10 Therapy protocols  
Over time and with growing experience, the therapy protocol applied to treat eBL at 
QECH changed a few times between 
1997 and 2009.(44,47,48,50) 
Between 1997 and 1999, the majority 
of the patient population received a 
therapy protocol consisting of COP, 
COMP and CYM in 6 cycles (Table 3.2). 
COP is vincristine (VINC), 
cyclophosphamide (CPM), prednisone 
and intrathecal methotrexate (MTX) + 
hydrocortison (HC). COMP is composed 
of CPM, VINC, intravenous MTX, 
prednisone and intrathecal MTX+ HC. 
Table 3.2. Chemotherapy Protocol 1997-1999 
Day 1 COP 1 
Day 8 COMP 1 
Day 22 COMP 2 
Day 36 CYM 1 
Day 50 CYM 2 
Day 64 COMP 3 
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CYM is intravenous and intrathecal cytarabine (ARA C), VINC, i.v. MTX with intrathecal 
MTX + HC. 
Between 2000 and 2002/2003, an alternative protocol was given consisting of overall 4 
cycles of COP and COMP.(47) Since 2003, most of the patients have received 4 cycles 
single agent CPM combined with intrathecal MTX+HC. Over the entire study period, 
treatment was adjusted to individual conditions in several patients.  
In the total patient population, 7.5% received a therapy with COP, COMP and CYM 
(1997-1999 schedule). 15.2% were treated according to the COP and COMP therapy 
protocol (2002 schedule), and 74.9% of the patients received a CPM + intrathecal MTX 
treatment (current schedule).   
3.1.11 Outcome  
The patients’ status regarding remission of lymphoma, progressive disease, relapse, or 
death was noted at discharge, at 1 month after discharge, at 6 months after discharge 
as well as at 12 months after discharge. In the following, the results are presented for 
each point in time. 
3.1.11.1 Outcome at discharge 
At discharge, 384 patients (80.2%) were tumour-free (first remission), whereas 66 
children (13.8%) had progressed or experienced relapse or death (Diagram 3.9, page 
24). Whether patients died of tumour disease, toxicity of chemotherapy or due to 
other reasons could not be sufficiently determined by means of documentation. There 
were 29 patients of whom no information about their tumour status at discharge was 
available which was mainly due to treatment abandonment. 
3.1.11.2 Outcome at 1 month 
At 1 month, 284 patients (59.3%) had remained in remission, whereas 110 patients 
(23.0%) had experienced an event like relapse or death (Diagram 3.10, page 25). In 85 
cases (56 additional cases to discharge), it was not possible to assess the tumour status 
as the patients did not show up for the follow-up appointment.  
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3.1.11.3 Outcome at 6 months  
At the follow-up appointment 6 months after discharge, 135 patients (28.2%) 
presented in continuous remission whereas 161 patients (33.6%) had had an event like 
relapse or death (76 additional cases) (Diagram 3.11, page 25). 183 (38.2%) of the total 
number of patients did not show up for the appointment at 6 months.  
3.1.11.4 Outcome at 12 months 
At the last follow-up appointment 12 months after discharge, 77 patients (16.1%) 
presented tumour-free in continuous remission, while in the meantime 13 additional 
patients had experienced relapse or death (Diagram 3.12, page 26). 
Overall, 174 patients (36.3%) had an event (relapse or death) during the 12 months 
control period. Almost half of the study population (228 patients, 47.6%) did not show 
up for the last appointment.   
 
Diagram 3.9 EFS at discharge (percent) 
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Diagram 3.10 EFS at 1 month (percent) 
 
 
 
 
Diagram 3.11 EFS at 6 months (percent) 
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Diagram 3.12 EFS at 12 months (percent) 
 
 
 
3.2 Statistical evaluations of simple correlations by contingency tables 
First, we characterized our patient cohort by analysing well-known risk factors and 
disease parameters in relation to outcome as well as eosinophilia. Next, we focused on 
the major question addressed in this thesis, if, to what extent and how eosinophilia is 
associated with various disease parameters and with treatment response and 
outcome. 
In the following, the results of simple correlations between particular parameters will 
be presented. Cross tabulation calculations were applied.  
3.2.1 Outcome  
3.2.1.1 Stage  
Based on the hypothesis that disease stage correlates inversely with 
outcome(65,93,96), statistical correlation between the stage and EFS at discharge, 1, 6 
and 12 months after discharge was undertaken.  
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Analysis were performed for variables STAGE A (stages I,II vs. III,IV) and STAGE B 
(stages I-III vs. IV), the two binary variables for the stage parameter. 
3.2.1.1.1 At discharge 
According to the results and as anticipated, patients with stage I or II disease had a 
significantly better outcome than patients with stage III or IV (chi-square 0.005; OR 
2.439 [1.304-4.562]). However, patients with stage I-III did not have a significantly 
better outcome than patients with stage IV (chi-square 0.256) (Diagram 3.13, page 28). 
3.2.1.1.2 At 1 month after discharge 
As expected, patients with stage I or II disease showed a significantly higher EFS at 1 
month after discharge than stage III and IV (comparison STAGE A) (chi-square 0.035; 
Odds Ratio (OR): 1.688 [1.040-2.739]).  
In comparison STAGE B, patients with stage I-III disease showed significantly more 
often a better outcome free of recurrence or death (chi square 0.013 OR: 2.191 [1.211-
3.964]) than patients with stage IV disease (Diagram 3.14, page 28). 
3.2.1.1.3 At 6 months after discharge 
At 6 months, stage I or II did correlate significantly with better EFS (chi-square 0.010 
OR: 1.918 [1.177-3.125]), whereas comparison STAGE B (I-III vs. IV) showed a 
significant simple correlation between stage I-III disease to EFS (chi-square 0.011 OR: 
2.621 [1.258-5.459]) (Diagram 3.15, page 29).   
3.2.1.1.4 At 12 months after discharge 
As expected, a significant simple correlation between the variable STAGE A and EFS at 
12 months was found. Patients with stage III or IV disease had a significantly reduced 
probability of EFS than patients with stage I or II disease (chi-square 0.042 OR: 1.815 
[1.038-3.174]) (Diagram 3.16, page 29).  
Analysing the correlations between the variable STAGE B and outcome at 12 months, a 
significant correlation between the status of stage I-III and EFS was found (chi-square 
0.051 (OR: 2.518 [1.002-6.329]).  
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Diagram 3.13 EFS at discharge by stage (percent) 
 
 
 
Diagram 3.14 EFS at 1 month by stage (percent) 
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Diagram 3.15 EFS at 6 months by stage (percent) 
 
 
 
Diagram 3.16 EFS at 12 months by stage (percent) 
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3.2.1.2 Localisation  
The hypothesis is that patients with tumour exclusively located in the facial area have 
an improved outcome over patients with any abdominal manifestation.(92) According 
to this assumption, statistical evaluations correlating in cross tabulations the location 
sites to the outcome at discharge, at 1, 6 and 12 months after discharge were 
undertaken.   
As previously described, there were two variables categorizing the localisation 
parameter. To recall their structure, LOCALISATION A compares exclusive facial 
manifestation with exclusive abdominal manifestation whereas LOCALISATION B 
compares absence of abdominal manifestation with presence of any abdominal 
manifestation. These classifications are based on previous data demonstrating a worse 
prognosis in case of abdominal manifestations of the tumour.(74,92)     
3.2.1.2.1 At discharge 
As anticipated, an exclusive facial manifestation correlated significantly with first 
remission (chi-square 0.011 OR: 2.262 [1.239-4.127]).  
Moreover, absence of abdominal tumour manifestation correlated clearly significantly 
with EFS (chi-square 0.007 OR: 2.124 [1.237-3.647]) (Diagram 3.17, page 31).  
3.2.1.2.2 At 1 month after discharge 
LOCALISATION A: A marginal non-significant correlation between a facial manifestation 
only and EFS was found (chi-square 0.061 OR: 1.674 [0.998-2.809]).  
LOCALISATION B: Again, a marginal, non-significant correlation between absence of 
abdominal manifestation and EFS (chi-square 0.056 OR: 1.578 [1.012-2.460]) was 
found (Diagram 3.18, page 32).  
3.2.1.2.3 At 6 months after discharge 
Both LOCALISATION A and LOCALISATION B showed significant correlations with 
outcome at 6 months. Analysis with the former variable (A) showed that patients with 
an exclusive facial manifestation had significantly higher EFS than those with an 
exclusive abdominal manifestation (chi-square 0.009 OR: 2.117 [1.222-3.667]). The 
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statistical analysis with the latter variable (B) showed with a similar significance (chi-
square 0.005) that patients with no abdominal tumours at all had higher EFS than 
those with any abdominal manifestation (OR: 1.964 [1.234-3.128]) (Diagram 3.19, page 
32).  
3.2.1.2.4 At 12 months after discharge 
Using the variable LOCALISATION A with regard to outcome at 12 months, a significant 
simple correlation of EFS with an exclusive facial manifestation could be shown (chi-
square of 0.039; OR: 2.010 [1.045-3.865]).  
Furthermore, within variable LOCALISATION B, patients without abdominal 
manifestation had a significantly increased EFS at 12 months after discharge (chi-
square 0.028; OR: 1.900 [1.103-3.273]) (Diagram 3.20, page 33).  
 
Diagram 3.17 EFS at discharge by localisation (percent) 
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Diagram 3.18 EFS at 1 month by localisation (percent) 
 
 
 
Diagram 3.19 EFS at 6 months by localisation (percent) 
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Diagram 3.20 EFS at 12 months by localisation (percent) 
 
 
 
3.2.1.3 CNS manifestation 
To address whether CNS manifestation of eBL had a negative effect on outcome in our 
patient cohort as it has been shown for sBL (23), statistical comparisons between 
patients without and patients with CNS manifestation with regard to EFS at discharge, 
1, 6 and 12 months after discharge were performed.  
At none of the four dates (discharge, 1, 6 and 12 months after discharge), a significant 
simple correlation between CNS manifestation and outcome was found (chi-square at 
discharge 0.609; at 1 month 0.123; at 6 months 0.164; at 12 months 0.598). Odds 
ratios are as following: discharge 1.305 [0.517-3.290], 1 month 1.889 [0.846-4.215], 6 
months 2.117 [0.790-5.674], and 12 months 1.674 [0.524-5.181]. 
3.2.1.4 Paraplegia 
To show potential correlation between paraplegia/incontinence and EFS, cross 
tabulation calculations were performed. The results did not show a significant 
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correlation, neither negative nor positive, at any of the four control dates (chi-square 
discharge: 0.798, 1 month: 0.234, 6 months: 0.060, 12 months: 0.071).  
Odds ratios are as following: discharge 1.084 [0.402-2.923], 1 month 1.719 [0.721-
4.094], 6 months 3.544 [0.979-12.830], 12 months 5.630 [0.719-44.087]. 
3.2.1.5 Bone marrow involvement 
Bone marrow involvement by Burkitt lymphoma cells has been previously shown to 
reduce tumour free survival in sBL cases.(23) Therefore, correlations of bone marrow 
involvement to outcome at discharge and at 1, 6 and 12 months after discharge were 
performed.  
No significant correlations between bone marrow involvement by lymphoma cells and 
reduced EFS were found at discharge, 6 months and 12 months after discharge (chi-
square at discharge 0.593; at 6 months 0.118; at 12 months 0.563). Odds ratios were 
between 1.242 [0.453-3.404] at discharge, 2.766 [0.868-8.812] at 6 months, and 1.844 
[0.503-6.758] at 12 months. 
However, a significant correlation between outcome with event and bone marrow 
involvement by Burkitt lymphoma was shown at 1 month after discharge (chi-square 
0.047 OR 2.460 [1.026-5.902]).  
3.2.1.6 Parasitic infections 
As described in the general characterization of the patient population, the patients 
were assessed for parasitic infections at diagnosis.  
Parasitic infections are known to contribute substantially to burden of disease in Sub-
Saharan Africa, partly due to high mortality rates, partly due to chronic ill-health.(143-
145) In 2010, almost 10 000 Malawian children under 5 died due to malaria, and about 
6 000 children under 5 died due to diarrhoeal diseases.(146) In total, about 56 000 
children under five years died.(146) 
Because of its weakening effects on the physical condition of the patients and its 
contributions to deaths and morbidity in Sub-Saharan Africa(78,133,142), a parasitic 
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infection could negatively affect outcome of lymphoma treatment. Further, 
eosinophilia is found in parasitic infection.(17,36,80,106,118) Since eosinophilia is a 
central subject of this study, it is necessary to analyse potential correlations between 
parasitic infections and outcome.  
To address the potential association of parasitic infection and outcome, statistical 
analyses for all 4 time-points were made.  
Neither malaria (chi-square 1.000 at discharge; 0.571 at 1 month; 0.088 at 6 months; 
0.236 at 12 months), nor parasites in stools (chi-square 0.567 at discharge; 0.480 at 1 
month; 0.272 at 6 months; 0.355 at 12 months) nor parasites in urine (chi-square 1.000 
at discharge; 1.000 at 1 month; 0.451 at 6 months, 0.261 at 12 months) correlate with 
EFS at any point in time.  
3.2.1.7 Age 
Previous studies on haematological cancers of childhood have addressed the 
importance of age as a risk stratification factor for outcome, mortality and survival 
(85,91,125,137), some of which with specific focus on NHL or Burkitt lymphoma 
(8,19,22,23,86,93,98,125). Here, we assessed the impact of age on outcome at all 4 
time points.  
Statistical evaluation by univariate cross tabulation calculation did not reveal any 
significant correlation between age group and EFS at any of the given dates (discharge: 
0.274, 1 month: 0.136, 6 months: 0.524, 12 months: 0.772). 
3.2.1.8 Sex 
Since sex has previously been discussed as a factor affecting outcome of paediatric 
lymphoma and other haematological malignant diseases (8,19,86,93,125,137), we 
analysed our cohort with regard to age groups.  
Significant correlations between age and EFS were not found at any time point (chi-
square at discharge 0.677; at 1 month 0.412; at 6 months 0.463; at 12 months 0.387). 
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Odds ratios were 0.886 [0.516-1.520] at discharge, 0.817 [0.518-1.288] at 1 month, 
0.815 [0.503-1.320] at 6 months, and 0.758 [0.425-1.352] at 12 months. 
3.2.1.9 Therapy protocol  
As previously described, the applied therapy protocols were changed and adjusted 
several times during the study period. To evaluate a possible influence of the individual 
therapy protocols on outcome, simple correlation calculations were performed.  
At none of the 4 control dates, a significant correlation between the outcome and the 
applied therapy according to the individual treatment schedules was found (chi-square 
at discharge 0.527; at 1 month 0.376; at 6 months 0.933; at 12 months 0.642). Analysis 
with the binary therapy variable comparing the most recent therapy protocol to the 
former protocols also did not show significant correlations (chi-square discharge 0.634, 
1 month 0.177, 6 months 0.783, 12 months 0.744). Odds ratios were 1.248 [0.651-
2.393] at discharge, 0.684 [0.411-1.139] at 1 month, 0.849 [0.519-1.538], and 0.851 
[0.443-1.634] at 12 months.  
3.2.1.10 Blood counts 
In order to reveal potential interactions between various blood parameters and EFS, 
statistical analyses were performed. All blood values mentioned above were correlated 
with the EFS at all control points.  
3.2.1.10.1 Haemoglobin 
Severe anaemia is an important cause of death in sub-Saharan children.(2) The 
haemoglobin concentration and the presence or absence of anaemia were analysed 
with regard to their influence on EFS. Anaemia was defined as haemoglobin levels 
below the specified normal ranges, and severe anaemia as haemoglobin levels below 5 
g/dl.(24)  
The results did not show significant correlations for anaemia with outcome at 
discharge, 6 and 12 months. (Anaemia: chi-square: discharge 0.426, 6 months 0.585 12 
months 0.747; severe anaemia: discharge 0.326, 1 month 1.000, 6 months 0.417, 12 
months 0.172). Odds ratios for anaemia were 1.372 [0.702-2.679] at discharge, 1.169 
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[0.683-2.000] at 6 months, and 1.126 at 12 months. By contrast, at 1 month after 
discharge, anaemia significantly correlated with adverse outcome (chi square 0.047; 
OR 1.781 [1.007-3.153]. 
3.2.1.10.2 Leukocytes 
A study conducted in South Africa in paediatric ALL patients had revealed WBC > 20 
x10³/µl to be a predictor for poor outcome.(137) Here, total leukocytes and presence 
of leukopenia and leukocytosis were correlated with EFS.  
At none of the four control dates leukopenia had a significant correlation with EFS (chi-
square discharge: 0.295, 1 month 0.398, 6 months 0.385, 12 months 0.288). Odd 
ratios: discharge 1.704 [0.705-4.116], 1 month 1.395 [0.627-3.103], 6 months 1.512 
[0.614-3.721], and 12 months 2.327 [0.654-8.285]. 
Likewise, the cross tabulation calculations of leukocytosis and EFS did not result in 
significant correlations at any of the 4 control points (chi-square discharge 0.791, 1 
month 0.880, 6 months 0.758, 12 months 1.000). Odds ratios: discharge 1.154 [0.584-
2.283], 1 month 1.080 [0.601-1.942], 6 months 1.128 [0.614-2.074], and 12 months 
1.026 [0.502-2.095].  
3.2.1.10.3 Neutrophils 
Absolute neutropenia and neutrophilia were correlated with EFS at all 4 control points.  
There was no significant correlation between absolute neutropenia and EFS at any of 
the four control dates (chi-square discharge 0.403, 1 month 0.906, 6 months 0.542, 12 
months 0.467). (OR: discharge 0.771 [0.438-1.359], 1 month 1.035 [0.653-1.643], 6 
months 0.856 [0.530-1.382], 12 months 0.799 [0.454-1.406]) 
Absolute neutrophilia did not correlate with EFS at any of the control dates (chi-square 
discharge 1.000, 1 month 0.223, 6 months 0.445, 12 months 0.599). OR: discharge 
1.035 [0.513-2.089], 1 month 1.451 [0.820-2.569], 6 months 1.293 [0.703-2.377], 12 
months 0.819 [0.417-1.607]. 
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3.2.1.10.4 Lymphocytes 
Cross tabulations were performed with both absolute and relative lymphopenia and 
lymphocytosis and EFS.  
Absolute lymphopenia significantly correlated with lower EFS at discharge, with a chi-
square of 0.019 (OR 2.720 [1.234-5.995]). Besides, no further significant correlations 
were found for any of the other time points. (Absolute lymphopenia: chi-square 1 
month 0.305, 6 months 1.000, 12 months 0.799; OR 1 month 1.476 [0.682-3.192], 6 
months 0.989 [0.428-2.286], 12 months 1.250 [0.434-3.604]. 
Analysis of absolute lymphocytosis and outcome did not show any significant 
correlations (chi-square discharge 0.413, 1 month 0.910, 6 months 0.478, 12 months 
0.489). The odds ratios were 0.776 [0.457-1.317] at discharge, 0.971 [0.621-1.518] at 1 
month, 0.825 [0.518-1.313] at 6 months, and 0.813 [0.470-1.408] at 12 months. 
Concerning relative lymphopenia, chi-square at discharge was 0.163, at 1 month 1.000, 
at 6 months 0.569, and at 12 months 0.376. Odds ratios were at discharge 1.768 
[0.801-3.901], 1 month 0.924 [0.433-1.972], 6 months 0.769 [0.365-1.621], 12 months 
0.683 [0.295-1.582]. 
Also, for relative lymphocytosis no significant correlation with EFS at any of the control 
times was found (chi-square: discharge 0.214, 1 month 0.703, 6 months 0.083, 12 
months 0.542; OR: discharge 0.689 [0.387-1.227], 1 month 0.911 [0.554-1.498], 6 
months 0.611 [0.357-1.044], 12 months 0.806 [0.436-1.488]). 
3.2.1.10.5 Monocytes 
Absolute and relative monocytosis was correlated with EFS at every time point.  
For absolute monocytosis, no significant correlations could be shown (chi-square 
discharge 0.890, 1 month 0.107, 6 months 0.552, 12 months 0.778). Odds ratios 
constituted at discharge 0.961 [0.557-1.658], 1 month 0.688 [0.438-1.080], 6 months 
0.860 [0.539-1.374], 12 months 0.891 [0.512-1.551].  
Concerning relative monocytosis, at none of the four control points a significant 
correlation was found (chi-square discharge 0.892, 1 month 0.088, 6 months 0.289, 12 
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months 0.889). The odds ratios were 1.054 [0.617-1.798] at discharge, 0.670 [0.427-
1.052] at 1 month, 0.775 [0.487-1.235] at 6 months, 1.067 [0.617-1.846] at 12 months. 
3.2.1.10.6 Eosinophils 
The major hypothesis underlying this analysis is that eosinophilia in patients with eBL 
significantly affects outcome. To our knowledge this question has not been addressed 
in previous studies. Statistical comparisons of patients without eosinophilia and 
patients with absolute eosinophilia with regard to EFS at the various time points were 
done. Eosinophilia was defined according to a standard reference source (see Table 2.2 
in chapter 2.4, page 10). 
The contingency table analysis for outcome at discharge showed that eosinophilia does 
not correlate significantly to EFS (Diagram 3.21, page 40). Chi-square was 0.644 and 
the odds ratio added up to 0.831 [0.445-1.553].  
At 1 month time, a significant correlation between eosinophilia and outcome could be 
shown (Diagram 3.22, page 40). Chi-square constituted 0.038 and odds ratio was 0.552 
[0.318-0.958].  
At 6 months-time, no significant correlation between eosinophilia and EFS was found 
(chi-square 0.205; 0.688 [0.396-1.197]) (Diagram 3.23, page 41).  
At the last control time (12 months), we again found a significant correlation between 
the two variables presenting a chi-square of 0.053 and an odds ratio of 0.532 [0.289-
0.978] (Diagram 3.24, page 41).  
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Diagram 3.22 EFS at 1 month by eosinophilia (percent) 
 
 
Diagram 3.21 EFS at discharge by eosinophilia (percent) 
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Diagram 3.23 EFS at 6 months by eosinophilia (percent) 
 
 
 
 
Diagram 3.24 EFS at 12 months by eosinophilia (percent) 
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3.2.2 Eosinophilic counts, its characteristics and correlations 
Besides the effects on outcome, potential correlations of eosinophilia with various 
alternative parameters were assessed. These analyses were performed in order to 
identify confounding parameters. Corresponding to the paragraphs above, statistical 
calculations were done by using contingency tables.  
3.2.2.1 Tumour stage 
Further, tumour stage and the respective binary variables were correlated with 
eosinophilia. Statistical significant correlations were found between eosinophilia and 
stage (chi² 0.000). Analyses with the binary variables revealed a significant correlation 
of eosinophilia with STAGE A (chi-square 0.000 OR: 0.380 [0.247-0.582]) by an inverse 
correlation between eosinophilia and stage III and IV. Accordingly, stage B and 
eosinophilia correlate significantly (chi² 0.017; OR: 0.427 [0.210-0.866].  
3.2.2.2 Tumour localisation 
Eosinophilia was correlated with localisation and the two binary variables. Eosinophilia 
was found to correlate significantly with the nominal variable localisation (chi-square 
0.013) presenting more often in patients with facial tumours. In detail, a significant 
inverse correlation of eosinophilia with exclusive abdominal manifestation was found 
(LOCALISATION A) (chi-square 0.003 OR: 0.451 [0.267-0.762]). Similarly, the statistical 
analysis revealed a significant correlation of eosinophilia with LOCALISATION B 
presenting an inverse coherence between eosinophilia and abdominal manifestation 
(chi-square 0.001 OR: 0.497 [0.324-0.762]).  
3.2.2.3 Parasitic infections 
Eosinophilia is a physiological defence mechanism to most parasitic infections 
including schistosomiasis, hookworm infection and strongyloidiasis.(17,36,80,106,118) 
In contrast, malaria can be associated with eosinopenia.(25,127) Thus, it is conceivable 
that eosinophilia at diagnosis may be related to parasitic infections. Therefore, a 
statistical analysis of the association of parasitic infections with eosinophilia was done.  
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Parasites in the urinary tract (e.g. Schistosomiasis haematobium) significantly 
correlated with eosinophilia (chi-square 0.000 OR: 3.462 [1.855-6.463]). By contrast, a 
positive microscopy for parasites in stools did not show a significant correlation to 
eosinophilia (chi-square 0.106, OR: 2.015 [0.869-4.673]). 
Malaria did not correlated with eosinophilia (chi-square 0.706, OR: 0.817 [0.375-
1.781]). 
3.2.2.4 Bone marrow involvement 
As eosinophilia had previously been found to be correlated with bone marrow 
involvement in NHL in adults (71), we analysed correlation between bone marrow 
involvement and eosinophilia in our study cohort. 
There was a trend for correlation of bone marrow involvement and eosinophilia which 
did not reach statistical significance (chi² of 1.000, OR: 0.869 [0.368-2.181]).  
3.2.2.5 CNS manifestation 
CNS involvement is a risk factor in NHL and Burkitt lymphoma.(74,87) An association of 
CNS involvement in NHL with eosinophilia has previously not been reported in the 
literature. Here, potential correlations between CNS involvement and eosinophilia 
were analysed.   
A significant correlation of the two variables was revealed (chi-square 0.043; OR: 0.336 
[0.116-0.974]) showing an inverse correlation between eosinophilia and CNS 
involvement. 
3.2.2.6 Sex 
As sex has been subject of a number of studies concerned with outcome in paediatric 
NHL (19,20,22,86,93), eosinophilia was correlated with sex to identify a potential 
correlation. No significant correlation between sex and eosinophilia was found (chi-
square 0.296; OR: 1.318). 
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3.2.2.7 Age 
The significance of the age of patients for outcome has also been widely studied in 
NHL.(19,20,86,93) Here, we analysed potential associations between patient age and 
eosinophilia. Results did not show a significant correlation between the two variables 
(chi-square 0.318). The odds ratio for patients younger than 10 years in comparison to 
patients 10 years or older was 0.893.  
3.3 Statistical analysis of complex correlations by Generalized Linear Model 
As univariate correlations have revealed several factors affecting outcome and 
eosinophilia, further statistical analyses were required in order to reveal associations 
among the identified factors and to identify independent parameters with an 
independent impact on outcome of eBL treated with chemotherapy.  
A generalized linear model was configured to allow for an interval-censored survival 
analysis. For this purpose, data had been prepared merging the four different points of 
control (discharge, 1 month, 6 and 12 months) to one large data set allowing us to 
analyse the interval-censored survival data.  
As detailed above, the following parameters have been previously identified to 
represent prognostic factors for survival of Burkitt’s lymphoma: Type of treatment, 
age, CNS involvement, BM involvement and stage of disease.(8,19,22,96,115) These 
parameters were imbedded into the multivariate analyses. According to the hypothesis 
underlying this work, eosinophilia respectively eosinophilic count were included as 
well.  
Results of this analysis showed a significant influence on outcome at any time point of 
this study solely for the variable stage. An increased probability of not experiencing an  
event within the 12 months study period was identified for patients with stage I or II 
disease while patients with more advanced disease (stage III or IV) are at higher risk for 
an event (chi-square 0.019 exp(B) 1.579 [1.082-2.359]). 
The analysis presented a tendency of older age groups to have an increased risk for an 
event during the 12 months time period in comparison to the younger age groups 
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(exp(B) 1.011 for 5-9 years old, 1.241 for 10-14 years old, 1.787 for 15 years and older). 
However, the age classification did not show a significant impact on outcome for any 
of the subgroups (wald chi-square of 0.961 for age group 5 to 9 years, 0.426 for age 
group 10 to 14 years, and 0.560 for age group 15 years and older). 
Involvement of CNS did not significantly interfere with the overall outcome (wald chi 
square 0.641), although there was a trend of CNS involvement to increase the 
probability of an event (exp(B) 1.155 [0.630-2.118]). 
Bone marrow involvement did not significantly correlate to outcome (chi-square 
0.381), although a trend was found for a worse outcome for patients with bone 
marrow involvement (exp(B) 1.341 [0.696-2.581]).  
The analysis did not show a significant impact of eosinophilia on outcome (chi-square 
of 0.215), although there was a trend towards a positive influence of eosinophilia on 
the outcome, with a lower likelihood of an event when eosinophilia was present 
(exp(B) 0.777 [0.521-1.158]). 
Table 3.3 shows a summary of the results of the generalized linear model.  
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Table 3.3 Generalized linear model Parameter estimates 
 
Parameter 
Regression 
coefficient 
B 
Standard 
error 
95% Wald-
confidence interval 
Hypothesis 
testing 
Exp(B) 
95% Wald-confidence intervall for 
Exp(B) 
Minimum 
value 
Maximum 
value 
Wald-
Chi-
Square df Sig. 
Minimum 
value Maximum value 
(Constant term) -2.211 .2693 -2.739 -1.683 67.445 1 .000 .110 .065 .186 
[Stage_Clas_1=1] .468 .1989 .078 .858 5.543 1 .019 1.597 1.082 2.359 
[Stage_Clas_1=0] 0 . . . . . . 1 . . 
[Local_cns=1] .144 .3093 -.462 .751 .218 1 .641 1.155 .630 2.118 
[Local_cns=0] 0 . . . . . . 1 . . 
[Local_bm=1] .293 .3343 -.362 .948 .769 1 .381 1.341 .696 2.581 
[Local_bm=0] 0 . . . . . . 1 . . 
[Clas_Age_1=4] .581 .9970 -1.373 2.535 .339 1 .560 1.787 .253 12.611 
[Clas_Age_1=3] .216 .2707 -.315 .746 .634 1 .426 1.241 .730 2.109 
[Clas_Age_1=2] .011 .2243 -.429 .451 .002 1 .961 1.011 .651 1.569 
[Clas_Age_1=1] 0 . . . . . . 1 . . 
[Eosinophilia_abs_w=1] -.253 .2039 -.652 .147 1.534 1 .215 .777 .521 1.158 
[Eosinophilia_abs_w=0] 0 . . . . . . 1 . . 
[Time=4] -.512 .4315 -1.357 .334 1.405 1 .236 .600 .257 1.397 
[Time=3] .891 .1966 .506 1.276 20.533 1 .000 2.437 1.658 3.583 
[Time=2] -.209 .2203 -.640 .223 .897 1 .344 .812 .527 1.250 
[Time=1] 0 . . . . . . 1 . . 
(Skala) 1          
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4 DISCUSSION 
4.1 Characteristics of study population 
The huge lack of information regarding predictors in outcome of eBL motivated us to 
address this topic. Only few comparable studies concerned with this subject exist. 
Therefore, first of all we characterized our study population and compared it to the 
existing literature. 
 
The characteristics of our study cohort are compatible with previous reports on eBL in 
Malawi and other sub-Saharan countries. This confirms the validity of our work and its 
adaptability to other countries with similar settings. In the following, we will shortly 
describe, compare and discuss details of our study population in reference to previous 
reports. 
  
With a total number of 479 cases included in the study, our study population was 
among the largest ever reported on endemic Burkitt lymphoma in Africa. There are 
some previous studies with comparable numbers of patients(12,94,100), some have 
included  more(4,34,98,119), others far less patients(46,128). A unique characteristic 
of our study compared to others on eBL in Malawi is the extensive detail with which 
we were able to describe our cohort.(47,65,119) 
Both median and mean of patients’ age were 7.00 years ranging from 1-18 years. 
These results are within the upper age range of findings made by other study groups 
on eBL in various African countries, ranging from 5.0 to 8.0 
years.(4,34,46,49,65,88,94,96,98,100,128) The slight differences in mean and median 
age of the study population could be due to the different approaches to adolescent 
patients. Some studies and also paediatric wards would only include or admit patients 
up to 15 years, whereas the upper age limit in our study was 18 years.  
48 
 
The boys to girls ratio of our patient group constituted 1.8:1 with a preference for male 
patients. Similar to the age characteristics, this finding matches results previously 
described for African eBL.(4,8,12,34,65,94,96,100) In comparison, studies made in 
Northern and Southern Brazil where it is still uncertain which type of BL is dealt with 
give slightly higher ratios for males with 2:1 or 2.2:1.(41,116)  
4.1.1 Stage of disease 
The distribution of stage in our study was as follows: 14.4% stage I, 22.3% stage II, 
46.8% stage III and 15.2% stage IV. This means about 62% of the patients presented 
with extensive disease on admission. Although this distribution is similar to some 
previously reported numbers(47), all in all, our cohort had a rather low proportion of 
advanced stages than others: The stage distribution found in a recent study with 129 
patients in Cameroon had a proportion of 82% of the patients presenting with 
extensive disease.(49) Moreover, investigators of BL and Burkitt-like lymphoma in the 
French-speaking African countries also found a larger part of their study population in 
stage III and IV 76.1%.(128) Possible explanations could be an improved awareness in 
Malawi for Burkitt lymphoma and its symptoms due to the successful work of the 
oncologists at QECH enabling patients and their parents to search help at earlier 
stages. It should further be noticed that before the early 1990s and partly until to date, 
staging was or is conducted according to the system modified by Magrath and Ziegler 
(59, 99, 108, 109) which differs from the St Judge classification used nowadays in most 
of the centres and hospitals.(97,98,134) (152 cit. a. 117) This must be taken into 
account for any comparisons concerning staging.    
4.1.2 Localisation 
In our patient cohort, the majority (48.4%) had a sole facial tumour manifestation, 
27.3% of the patients had an exclusive abdominal localisation, and 20% had both facial 
and abdominal involvement. Only 4% presented with other rarer manifestation sites. 
In total 47.4% of the patients presented with any abdominal and 68.4% with any facial 
manifestation. These results are congruent with findings of other studies showing 
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similar localisation patterns.(4,12,47,65,96,100) However, some studies have reported 
abdominal involvement at admission to be more frequent.(34,49,128) This discrepancy 
to our results might be due to an insufficient assessment of abdominal involvement in 
our patient cohort. Reasons could be lacking quality or availability of ultrasound 
devices, missing documentations, or deficient training in ultrasound diagnostics of the 
local staff. However, it could also be due to actual regional differences in the 
characteristics of eBL. Moreover, it is supposable that the entity of eBL is hard to 
diagnose reliably in actual on-site settings despite extensive efforts by the WHO to give 
clear definitions. This could possibly lead to improper diagnosis, discrepancy of 
characteristics in different locations and to falsified statistics.  
Some other studies did not differentiate between sole abdominal versus facial 
manifestation so that comparisons with our cohort are not 
possible.(4,47,49,94,96,100) 
4.1.3 CNS involvement & BM involvement 
Eight percent of our study population presented with CNS involvement, 7.5% with 
paraplegia (6.5%), incontinence (1.0%) or both (3.8%), and 6.7% with involvement of 
the bone marrow. Heterogeneous frequencies of CNS involvement have been reported 
in various studies. One of the first major works on CNS involvement in eBL was 
conducted and published by Ziegler in 1970. It stated that 18.4% of the study 
population presented with CNS involvement at diagnosis.(151) Moreover, a study from 
1980 in Uganda showed a high percentage of 30% presenting with CNS 
involvement.(96) By contrast, others reported much lower incidence of CNS 
involvement: Publications by Owusu on eBL in Ghana stated CNS involvement in only 
3.3% of the cases(100) or by Hesseling on eBL in Cameroon in 4% of the patients(49). 
Another recent publication found 8.2% of their patients with a positive cerebral spinal 
fluid for BL cells, comparable to our own observation.(92) Furthermore, the extensive 
literature work of Non-Hodgkin Lymphoma in general reports numbers of 19% of the 
patients having CNS involvement.(79)  
50 
 
It should be critically noted that, as we found, CNS involvement is often not exactly 
defined which excludes valuable comparisons on this subject. In detail, CNS 
involvement can be characterized by positive cerebrospinal fluid only, or may include 
patients with any sign of neurological involvement (paraplegia, incontinence, cranial 
neuropathy, altered consciousness, etc.) even in the absence of BL cells in CSF.(151) In 
our retrospective study we cannot be certain if all patients with CNS involvement 
noted in their file did actually get a lumbar puncture or if CNS involvement was simply 
assumed from clinical appearance.  
An indirect parameter indicating CNS involvement is paraplegia. Compared to our own 
finding of 6.5% paediatric eBL patients presenting with paraplegia, a previous study 
from Malawi stated a percentage of 12% with paraplegia among the study population 
of eBL (47). By contrast, only 3.1% of the patients in a recent study from Tanzania were 
paraplegic.(92) The differences may at least partly be explained by the fact that the 
study in Tanzania did not only include children and adolescents but also adults which 
may have different disease manifestations than children. 
 
Concerning bone marrow involvement, numbers published range from 4.2% to 
14%.(14,47,49,79,92,128) In 1979, Magrath and Ziegler discussed comprehensively the 
subject of BM involvement in BL in a review as at these times clear definitions of and 
differentiations between BL and acute B-cell leukaemia did not yet exist.(75) For this 
reason, they were calling for more detailed diagnostics, including examination of 
surface markers, in these patients. According to their results, 7% of the patients 
presented with BM involvement at admission. The percentage of BM involvement in 
our cohort is within the value range of results by other studies. However, since bone 
marrow aspirates were not done comprehensively for all patients, the incidence of BM 
involvement could be underdiagnosed. 
4.1.4 HIV 
Our patient cohort included 4.8% HIV-positive patients. This result is congruent with 
findings previously made in Malawi and Uganda.(98,102,119) The recent study in 
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Cameroon found 2.9% of the patients to be HIV-positive.(49) In a study conducted by 
GFAOP (Groupe Franco-Africain d'Oncologie Pédiatrique), 3.8% of the examined 
patients were found to be HIV-positive.(128)   
The subject of HIV and eBL is complicated by the recent WHO classification which 
differentiates not only between endemic and sporadic BL but includes an additional 
type associated with HIV (“HIV-related BL”).(61) Interestingly, the study in Uganda on 
NHL showed that there was no association between endemic childhood BL and HIV-
infection.(102) Despite the fact that WHO tried to imply specific definitions and 
diagnostic characteristics, approaches to paediatric patients with BL and HIV are still 
inconsistent.  As already proposed by Orem, there should be more work on HIV and 
paediatric eBL in order to clarify if there is a specific HIV-related BL besides eBL in 
African children.(97) Since there seems to be no consistent guideline, patients with 
HIV-infection and BL included in studies on eBL in Africa should be separately analysed.    
4.1.5 Anaemia 
The median haemoglobin level of our patients was 10.30 g/dl. Comparable results 
were found in Cameroon 2012 (mean: 9.8 g/dl)(49), in the multi-centre study from 
French speaking Africa 2008 (median 9.9 g/dl)(128), and in Nigeria 1979 (mean 9.87 
g/dl) (33).  Anaemia was found in 78% of the patients, severe anaemia in 1.9%.  
Even though anaemia was not further defined in their work, Orem et al. found 48.73% 
of the patients with anaemia in their retrospective study.(98) Lim & Peh found 66% of 
their paediatric and adult NHL patients to have anaemia and 80% of the BL cases 
within this group.(71) Used reference values were similar to ours. The high proportion 
of anaemia in all studies including ours is at least partly explained by the association of 
eBL with malaria. 
4.1.6 Parasites, Malaria 
We found that 9.4% of our patients had malaria at presentation. In comparison, 
Hesseling et al. described 17% of their patients in Cameroon to have malaria on 
admission.(49) The 2000 Burkitt lymphoma trial found 26% of the patients to have 
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malaria at admission.(47) In the large retrospective study of Orem et al. in Uganda, 
4.7% of the patients had severe or recurrent malaria.(98) However, the characteristics 
‘severe’ and ‘recurrent’ were not further defined throughout the publication. Our 
study design did not allow us to differentiate between malaria of varying severity. This 
complicates comparisons with alternative investigators.  
Parasitic infections of the bowel system were found in 6.0% of all tested children and 
included hookworms, Strongyloides stercorales, Gardia lamblia, Schistosomiasis 
mansoni, and Taenia). Eleven percent had urinary parasitic infections with 
Schistosomiasis haematobium. Some other studies also provide information on 
parasitic infections even though it is not mentioned in detail how many study patients 
were tested. For example, Hesseling et al. found among 129 patients in Cameroon 4 
cases of Ascacris lumbricoides, 3 Gardia lamblia, 1 Ancylostoma, 1 Schistosoma 
mansoni, 1 Trichuris trichuris, 1 Entamoeba histolytic and 1 Entamoeba coli.(49) 
As a national survey in Malawi revealed, 0.4% of Malawian children between 6 and 17 
years (mean 10.7 years) are infested with S. mansoni, 6.9% with S. haematobium, 1.3% 
with Hookworm, 0.5% with Ascariasis, and 7.7% have mixed infections. By stool 
microscopy,  1.8% of the cases had a parasitic stool infection.(15) In comparison to our 
results, this cross sectional-study had a lower prevalence of parasitic stool infections 
than our patient population. Similarly, S. haematobium infection of the urinary tract 
was much more common in our population compared to the mentioned study. This 
raises the question on how parasitic infection and eBL might be related.  
4.1.7 Therapy outcome  
In our cohort, 85.3% (respectively 80.2% of total patient population) of the patients 
assessable at discharge showed complete response to initial therapy and did not 
experience an event like relapse or death to the date of discharge. At 1 month after 
discharge, 72.1% (59.3%) cases were tumour free and alive whereas 27.9% (23.0%) of 
the patients experienced death or relapse. Analysis at later time-points is complicated 
by the high rate of patients lost to follow-up, thus, data must be analysed with care. 
Until 6 months after discharge, EFS was 45.6% (28.2%) and 54.4% (33.6%) experienced 
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an event. At 12 months, 30.7% (16.1%) had EFS while 69.3% (36.6%) had experienced 
an event. 
Comparison of these survival rates to previous reports is complicated by the following 
issues: 
The largest problem of our study was the high number of censored cases with 
incomplete documentation concerning their outcome status. While 479 cases where 
included generally, there were already 6% of the patients whose health status at 
discharge was not obtainable. At 12 months after discharge, there was no information 
on nearly half of the study population. This lack of data carries a high risk of bias and 
impairs comparability with prospective studies and overall quality. Why do the data 
lack quality, and why is it so difficult to obtain accurate documentation of outcome at 
follow-up? As elaborated in the introduction, Malawi is one of the poorest countries in 
the world. Access to and expenditure for health care are sparse. The need for follow-
up studies requiring apparently healthy former patients to come back to hospital for a 
certain time may be difficult for patients and parents/guardians to comprehend, 
considering the poor economic status of most of these patients. If the child died, it 
might not be worth the economic effort for parents/guardians to go to QECH to give 
notice. If the child is well and does not have problems, parents do not understand why 
they should spend money for transportation to QECH. It should also be considered that 
even if the families are willing to come back for follow-up, there may simply be no 
money for transport. This aspect was also discussed by Hesseling et al.(50)  
For research teams visiting patients at home, it may be difficult to find patients, as 
exact addresses do not exist in most parts of Malawi. Cultural differences should also 
be considered. The concepts of health and sickness partly differ in different cultural 
backgrounds.(42) Study concepts set from our Western perspective should consider 
and respect these aspects.  
Another issue is accuracy in documentation and diagnosis in the hospital which might 
be a problem. As Ogwang et al. showed the accuracy of histological BL diagnosis by 
local pathologists in low-income countries might be reduced.(95)  
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Despite these limitations, we have tried to compare our own data to previously found 
survival rates. Table 4.1 (page 55) shows a comprehensive overview of studies 
conducted on survival in eBL. 
A recent study from 2012 in Cameroon including cases between 2008 and 2009 
achieved an overall 1 year EFS of 61% using a risk adapted treatment.(49) Another 
study conducted in 2009 at QECH found an overall survival rate of 47.5% at 1 year.(48) 
The 2000 Burkitt lymphoma trial in Malawi included 42 cases and found a projected 
EFS at 1 year of 33% for all patients.(47) Our patient cohort included the patients of 
this study. Therefore, data and results are overlapping. Orem et al. found in their 
comprehensive retrospective work on the years 1985 to 2005 that 44.5% of their 
Ugandan patients achieved complete remission on initial therapy.(98) Follow-up times 
up to 13 years were mentioned, however detailed information on 1 year EFS or long-
term survival were not given.(98) In another study from Uganda, 81% of patients were 
found to have a complete response to chemotherapy leaving hospital in a tumour-free 
status.(8,96) This is comparable to our findings of 85.3%. However, it should be 
considered that the Ugandan study was performed between 1967 and 1977. 25% of 
these Ugandan patients had a 5-year OS. Unfortunately, there is no detailed 
information on EFS or OS after 1 year.(96) In 1967, Morrow at al. reported that 21% of 
the patient population in Mulago, Uganda, had a long-term survival of at least 496 
days.(86) Arthur et al. conducted a retrospective study on eBL in the years 2000 to 
2007 in Ghana finding 14% of the patients to stay in complete remission (CR) after the 
induction phase.(8). Nkrumah et al. found 34% of Ghanaian paediatric eBL patients 
treated between 1968 and 1972 to be tumour-free, with a follow-up of 62 weeks to 
283 weeks.(93) Ngoma et al. published a 1 year EFS of 54% and 1 year OS of 67% in 
Tanzanian, Nigerian and Kenyan patients between 2004 and 2009.(92) 
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Table 4.1 Overview - Survival eBL studies and publications (arranged by publishing year) 
Author, 
Pub year 
Country Year Number of 
patients 
Therapy Outcome 
Present 
study, 2012 
Malawi 1997-
2009 
473  1 year EFS 30.4% 
Hesseling et 
al. 2012(49) 
Cameroon 2008-
2009 
129  
 
Induction CPM 40mg/kg + IT 
MTX + IT HC; consolidation 
risk adapted CPM +/- VCR, 
MTX 
Projected 1 year 
EFS 61% 
Ngoma et 
al. 2012(92) 
Tanzania, 
Kenya, 
Nigeria 
2004-
2009 
356 CPM 1200 mg/m2 i.v., day 1 
Vincristine 1·4 mg/m2, i.v., 
day 1 
MTX 75 mg/m2, i.v., day 1 
MTX 12 mg, IT days 1 and 8 
Cytarabine 50 mg, IT, day 4 
CR on initial 
therapy 75.8% 
1 year EFS 54% 
2 year EFS 52% 
1 year OS 67% 
2 year OS 62% 
Orem et al. 
2011(98) 
Uganda 1985-
2005 
1217 Combination of CPM, 
vincristine + MTX; 
IT MTX or cytosine 
arabinoside 
For CNS prophylaxis & 
treatment 
 
CR on initial  
therapy 44.5%  
Hesseling et 
al. 2008(48) 
Malawi 2006 40  CPM 40 mg/kg on day 1 and 
60 mg/kg on days 8, 18 and 
28; IT MTX 12.5 mg + HC 
12.5 mg on days 1, 8, 18, 28 
 
1 year EFS 47.5% 
Orem et al. 
2008(97) 
Uganda 1994-
2004 
158 HIV – 
70 HIV + 
 
combination of CPM, 
vincristine + MTX; 
IT MTX or cytosine 
arabinoside 
For CNS prophylaxis & 
treatment 
Mean survival 
time 
HIV – 85 months 
HIV + 55 months   
Long-term 
Survival (follow-
up up to more 
than 100 months) 
HIV- > 70% 
HIV+ > 30% 
Hesseling et 
al.(44,48) 
Malawi 2003-
2005 
140 Day 1: CPM 40mg/kg body 
weight i.v. + IT MTX 12.5mg 
Projected  EFS  
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Cameroon Day 8,15: CPM 40mg/kg 
body weight p.o. + IT MTX 
12.5mg 
(stage III-IV: D 29, 43, 57 
CPM 40mg/kg) 
Stage I-III > 50%  
Arthur et 
al.(8) 
Ghana 2000-
2007 
180 M-COMP) regimen, with or 
without doxorubicin 
Long-term 
survival (mean 
follow-up 58 
weeks (range: 24–
156 weeks)) 
13.6% 
Hesseling et 
al. 2005(47) 
Malawi 2000-
2002 
42 COP1:  300mg CPM, 1 mg 
vincristine + 60mg 
prednisone + IT MTX + HC 
COP2 (only for patients with 
larger tumour volumes, 
stage III or IV disease): CPM,  
2mg vincristine + IT MTX + 
HC 
COMP1+ 2: 500mg CPM, 
2mg vincristine, 60mg 
prednisone + 2g MTX. All 
doses calculated per body 
surface area.  
Projected 1 year 
EFS 33% 
Hesseling et 
al. 
2003(44,50) 
Malawi 1997-
1999 
44 
(stage I-III) 
Day 1 COP I 
Day 8a COMP I 
Day 22 COMP 2 
Day 36 CYM I 
Day 50 CYM 2 
Day 64 COMP 3 
Projected 1 year 
EFS  
Overall 57%  
Stage I 90% 
Stage III 52% 
Kazembe et 
al. 2003(65) 
Malawi 1991-
1997 
92  Long-term 
survival (follow-
up 29-104 
months)  
Disease limited to 
head: 63.5% 
Disease in 
abdomen+ other 
sites: 33.3% 
Overall: 55% 
Olweny et 
al. 1980(96) 
Uganda 1967-
1977 
280 1967-69 CPM 40mg/kg body 
weight i.v. 1-6 times 
1969-71 CPM 40mg/kg body 
CR on initial 
therapy 81% 
5-year OS 25%  
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weight I.v. or CPM, VCR, 
MTX p.o., Ara-C 
1971-1973 CPM 40mg/kg 
body weight i.v.+/- BCG 
(scarification) 
193-1975 CPM 40mg/kg vs. 
CPM 30mg/kg i.v. +VCR 
2mg/m² i.v. +MTX 15mg/m² 
p.o. (COM) 
1975 COM +/- IT MTX 15mg 
Nrumah et 
al. 1976(93) 
Ghana 1968-
1972 
110  CPM 40 mg/kg i.v.    
If no response after 2 doses: 
Vincristine 1.4 mg/m2, i.v. + 
MTX mg/m² p.o. day 1-4       
If nor response: Cytosine 
arabinoside 250 mg/m2 i.v. 
for 3 days                           
If Meningeal involvement: IT 
MTX 10 mg 
Long-term 
survival (follow-
up 62 to 283 
weeks) 33% 
Morrow et 
al. 1967(86) 
Uganda 1961-
1965 
55 Varying therapy protocols 
(cyclophosphamide, others), 
majority no more than 2 
cycles  CPM 40mg/kg body 
weight i.v.  
Long-term 
survival 
(minimum follow-
up 496 days) 21%   
 
CPM: Cyclophosphamide, VCR: Vincristine, Ara-C: Cytosine Arabinoside, IT: intra-thecal, MTX: 
methotrexate, HC: hydrocortisone 
EFS: event-free survival, OS: overall survival, CR: complete remission 
 
4.1.8 Differential white blood cell count 
The focus of our study was the role of eosinophils in paediatric eBL. Our patient 
population presented with a median level of 0.10 x10³/µl eosinophils and a mean of 
0.29 x10³/µl eosinophils (range: 0.00-9.50 x10³/µl). Findings obtained in previous 
studies from Nigeria and Uganda reported higher mean values of 0.824 x10³/µl (range: 
0.00-4.37 x10³/µl) (110) and 0.689 (range: 0.1-38.8), respectively.(121)  
About one quarter (25.5%) of our patients presented with eosinophilia and 38.6% with 
eosinopenia. With respect to the relative values of eosinophils, 24.0% had eosinophilia 
and 48.2% eosinopenia. No data from comparable patient cohorts with paediatric eBL 
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in Africa have been reported in the literature. In a study in Singapore on a wider 
spectrum of NHLs, including (non-endemic) BL, none of the 5 BL cases and 4% of all 
NHL patients presented with eosinophilia.(71) In India, Agarwal et al. found 19% of 
their childhood AML patients to present with eosinophilia. All in all, the lack of 
information about eosinophilia in a general childhood population in Malawi makes it 
difficult to discuss the findings. Our findings remain descriptive at this stage. Further 
prospective studies will have to address the frequency of eosinophil counts in children 
with eBL. 
A critical issue concerning analysis of the levels of eosinophils is the definition of 
eosinophilia and the analysis of eosinophilic counts and their documentation. As is the 
nature of retrospective studies, the process of analysis and the correctness of 
documentation cannot be reproduced. Another problem is the variable quality of data 
assessed during more than 10 years. On the one hand, this allows us to acquire data 
from a large study population, on the other hand, the analysis is hampered by the 
heterogeneity of diagnostics and treatment and the high number of individuals 
responsible for documentation and assessment.  
 
Besides eosinophils, we compared data extracted from full differential counts with 
previous reports on cohorts of children with eBL and/or NHL. 
 
The median value of white blood cells in the patient population was 8.50 x 10³/µl while 
the mean value was 8.97 x 10³/µl (range 1.70 to 57.40 x 10³/µl). There is little work on 
the WBC and its differentiation in eBL. Hesseling et al. found a mean WBC of 8.6 x 
10³/µl in their study population.(49) In a study analysing 153 eBL cases between 1960 
and 1975 in Ibadan, Nigeria concerning their leukocytic counts gave a mean of 10.157 x 
10³/µl (range 1.850-60.20 x 10³/µl).(32) Comparison with our cohort is complicated by 
the fact that the Nigerian study population included adults, as it was the case for some 
other studies conducted in Ibadan on eBL.(32,33) There is one further study analysing 
leukocytes and the sub-groups in 44 cases in Uganda from 1961.(121) A mean 
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leukocytic count of 8.003 x10³/µl was reported (range: 4.60-13.30 x10³/µl). All in all, 
our own results are well compatible with these previous reports. 
Eight percent of our patients had a leukopenic cell count according to our reference 
values whereas 17.3% presented with a leukocytosis.  
Lim & Peh have analysed a cohort of adult and paediatric NHL patients retrospectively 
and found 11% of them to be leukopenic and 26% with leucocytosis.(71) Of the BL 
patients (n=5) among their study population, none presented with decreased WBC and 
only 1 case had leucocytosis. 
 
Concerning neutrophils in peripheral blood, we found a median value of 3.64 x10³/µl 
and a mean value of 4.18 x10³/µl (range: 0.20-8.30 x10³/µl). The studies from Uganda 
and Nigeria on differential white blood count in eBL report comparable mean values of 
5.639 x10³/µl (range: 0.388-48.160 x10³/µl)(32) and 3.774 x10³/µl (range: 2.00-7.20 
x10³/µl)(121), respectively. Ganesan & Bakashi found a median value of 5.40 x10³/µl 
among their B-NHL paediatric patients in India.(37)  
In our study, 16.7% of patients presented with neutrophilia at first admission and 
36.3% with neutropenia. Data for comparison are scarce, and none are reported for 
eBL. In a retrospective study conducted in Singapore, 20% of adult and paediatric NHL 
patients presented with neutrophilia and 17% with neutropenia.(71) Of the 5 cases 
with BL within this group, none had abnormal neutrophilic counts.(71)  
 
The median value of lymphocytes in peripheral blood of our patients was 3.40 x10³/µl 
and the mean value was 3.70 x10³/µl ranging from 0.60 to 10.00 x10³/µl. Durodola 
found mean values of 3.387 x10³/µl (range: 0.697-16.830 x10³/µl) in Nigeria (32) and 
Stansfield a mean of 3.381 x10³/µl (range: 1.1-5.3 x10³/µl) in Uganda (121). Thus, 
results are comparable throughout studies with eBL patient populations in Africa. 
By definition, 33.0% of our patients had absolute lymphocytosis and 8.4% 
lymphopenia. Again, no data allowing comparison were previously reported from 
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studies with paediatric eBL. Lymphopenia was a common finding in adult and 
paediatric patients with NHL (>40%) and in BL (20%) in Singapore.(71) Lymphocytosis 
was found in 13% of all NHL patients and in 1 case of the 5 BL cases.(71) Bloomfield 
found 46% of adult NHL patients to have lymphopenia at diagnosis.(13) However, adult 
NHL and paediatric eBL must be considered different diseases.  
 
Monocyte levels of our patients also compared well with previous data reported from 
eBL patients. Median level of monocytes found in our patients was 0.60 x10³/µl and 
mean value was 0.79 x10³/µl (range: 0.00-8.50 x10³/µl). The Ugandan study found a 
mean of 0.438 (range: 0.07-1.2 x10³/µl) (111), and the Nigerian study found a mean of 
0.387 x10³/µl (range: 0.0-2.827 x10³/µl) (110). 
 
Altogether, due to the retrospective nature, our study design lacks the necessary 
power to provide solid data of blood counts at diagnosis in paediatric eBL. Our analysis 
elucidates the need for large prospective efforts in this regard. 
4.2 Prognostic factors and correlations 
We were able to show that our study population is comparable to other study 
populations in all relevant aspects and thus, despite the limitations by the 
retrospective nature, adequately represents patients with eBL in Malawi and Sub-
Saharan Africa. In the following step we will discuss our results regarding potential 
predictors of outcome. In summary, our results confirm known aspects, such as stage 
being an important predictor for outcome. Moreover, we find that eosinophilia may 
have significant association to outcome, making this parameter worth studying in a 
prospective manner in future studies. 
4.2.1 Stage  
Throughout follow-up, stage was consistently strongly correlated to outcome (dis: 
0.005, 1: 0.035, 6: 0.010, 12: 0.042). The OR at 12 months (1.815) indicates that 
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chances for survival at 1 year without event like death or relapse for patients in stage I 
or II is 1.8 times more likely than for stage III or IV patients. Nevertheless, it should be 
reminded that case numbers had diminished at 12 months-time and therefore critical 
interpretation is essential. 
These findings correspond to results of previously conducted studies.(8,74,96) 
Although using a different staging system, Olweny et al. have shown a significant 
correlation between stage and long-term survival in Uganda between 1967 and 
1977.(96) Moreover, Magrath et al. found a significant impact of stage on survival.(74) 
Further, Arthur et al. described a significant correlation between stage and outcome in 
Ghana.(8) In Uganda, Orem found an increased mortality rate in children diagnosed at 
advanced stages.(98) However, Ngoma et al. did not find a significant correlation 
between stage and EFS nor OS in eBL in Equatorial Africa.(92) Current therapy 
protocols for sBL in high-income countries, as performed by the BFM or the LMB 
groups, use stage as an important parameter for risk stratification.(79) Interestingly, 
Cairo et al. failed to identify stage as a significant risk factor in sBL performing Cox 
multivariate regression analysis in their large FAB LMB 96 study.(23) An explanation is 
that the prognostic importance of stage may have been overcome by effective 
therapies. 
4.2.2 Localisation  
Throughout follow-up, primary tumour site was a significant or nearly significant factor 
concerning the outcome of patients. Odds ratios at all 4 control dates are around 2, 
indicating a better outcome for patients not affected by abdominal tumour masses. 
These findings match results by Ngoma et al. in Equatorial Africa describing absence or 
presence of abdominal involvement as clearly defining two risk groups.(92) However, 
the end point of this study was CR, not EFS or OS. Already in 1974, Magrath et al. had 
described abdominal involvement to be an important determinant for prognosis.(74) 
Also Cairo et al. found the primary site of tumour to be a significant risk factor for EFS 
and OS in sBL.(23) However, comparisons between sporadic and endemic BL can only 
provide hints. 
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4.2.3 CNS involvement 
ORs (dis: 1.305, 1: 1.884, 6: 2.117, 12: 1.674) for CNS manifestation by positive CSF 
findings for BL cells were continuously above 1 throughout follow-up, indicating a 
negative impact of CNS involvement on outcome. Although statistical analysis did not 
reveal significant correlations between CNS involvement and EFS, a tendency was 
detected. Lack of significance might be due to the small number of cases with CNS 
involvement involved in our study.  
CNS manifestation is generally considered an important risk factor and is included into 
both the St Judes and Murphy staging system, classifying any CNS or BM involvement 
as stage IV.(87) Cairo et al. found that CNS involvement in sBL was associated with 
treatment failure.(23) Moreover, Nrukmah et al. described in 1976 that CNS 
involvement at presentation or during course negatively affected survival.(93) 
However, it appears that CNS involvement does not automatically imply a worse 
outcome.(103) Ngoma et al. failed to identify a significant correlation between CNS 
involvement and worse prognosis.(92) However, we again would like to refer to the 
difference in endpoints applied to their study and ours. Disparity with regard to the 
prognostic role of CNS involvement might be due to the therapy protocols which had 
been changing throughout the African paediatric oncology centres over time and 
locations.(44,48,92,92,98,128) Meanwhile IT MTX has become a common standard of 
therapy in most cases and is effective to prevent death from CNS relapse in many 
patients(48,93).  
Even though significance tests for paraplegia and outcome did not show any significant 
correlations, OR were continuously above 1, again indicating a tendency of paraplegia 
affecting outcome adversely. At 6 months, the risk of an event is 3.5 times higher for 
patients presenting with paraplegia than patients without. At 12 months, the risk is 
even 5.6 times higher to experience an event than for patients without paraplegia.  
To our knowledge, there are no studies concerned with the correlation of paraplegia 
and outcome respectively survival in eBL.  
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4.2.4 Bone marrow involvement 
Our findings on BM involvement and outcome suggest an increased risk of event 
during the 12 months control period – at discharge odds are 1.2 times higher than 
without involvement, at 1 month they are 2.5 times higher, at 6 months 2.7 times and 
at 12 months 1.8 times higher. Statistical analysis did reveal a significant chi²-value for 
1 month (chi² 0.047) but not for any other time point. Comparable studies concerning 
this aspect are scarce. Nevertheless, in the above mentioned study by Ngoma, patients 
with BM involvement are described to be slightly less likely to achieve CR though 
significance was neither found.(92) In sBL, the situation may be different: Cairo 
identified BM involvement as an independent risk factor for outcome in children with 
sBL.(23)  
4.2.5 Age 
Significance testing did not show any significant correlation for age and EFS at none of 
the control dates. Results of published studies with regard to the impact of age on 
survival in NHL and Burkitt lymphoma are highly 
variable.(8,19,20,22,23,85,86,91,93,98,125) Orem et al. identified significant 
differences in mortality between age groups in eBL in Uganda.(98) In the early 
beginnings of Burkitt lymphoma research in Africa, Morrow et al. reported a better OS 
in younger patients with eBL in Uganda.(86) On the other hand, in Ghana and a decade 
later, age was shown not to influence significantly EFS.(93)  
In sBL, the situation is also not finally resolved: Cairo et al. reported in 2012 that age 
was not significantly correlated to 3-year EFS in sBL.(23) Burkhardt et al. presented 
similar results from their German-European study on NHL including sBL.(19) In a prior 
study, Cairo and colleagues had reported that patients with Burkitt and Burkitt-like 
lymphoma at an age of 15 years or older had significantly more often worse 4-year EFS 
than patients below this age.(22) However, the cohort number was much smaller (less 
than half) than in the more recent study, and the study design was retrospective in 
comparison to the prospective setting of the study published in 2012.(22,23)  
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In summary, these data do not support risk stratification by age of patients at first 
diagnosis. Studies concerned with this subject differ in setting and, more importantly, 
in criteria and cut-offs. This might explain variability of results as presented above. In 
order to improve study comparability and reproducibility, age groups should be 
distinctly defined and prospectively assessed.   
4.2.6 Sex 
Our statistical analysis revealed a persistent decreased chance for girls to achieve 12 
months EFS. Odds ratios are about 1/5 decreased in comparison to boys. Nonetheless, 
Fisher’s exact testing did not show significance for any of the time points.   
As mentioned above, sex has been discussed in the context of paediatric 
haematological malignant diseases especially in ALL and cancer.(8,19,93,125,137) 
However, the impact of sex on outcome in NHL has not been assessed extensively.(19) 
Burkhardt et. al. did not find correlation between probability of EFS at 5 years and sex 
in paediatric BL in German-speaking Europe.(19) Data reported from eBL are limited. In 
1976, Nkrumah et al. identified female patients to have a significantly worse 2 year EFS 
in eBL in Ghana.(93) A study on prognostic markers in African BL in Ghana failed to 
show a significant correlation between sex and progression-free survival.(8)  
4.2.7 Therapy protocol  
Statistical analysis did not reveal any impact of therapy protocols on outcome. This is 
in contrast to prior studies conducted at the same institution which showed a 
significant improvement in EFS over time.(44,47,48,50,65) Our failure in reflecting the 
success in therapy improvement for eBL in Malawi might be due do the fact that we 
did not include any information about neither therapy completion nor treatment-
related toxicity and lethality. As we included all patients seen between 1997 and 2009 
with reasonable clinical documentation, cases might have been included who were not 
enrolled into one of the treatment study trials performed at times or who did not 
finish treatment protocol. In such patients, therapy might not have been as carefully 
and thoroughly realised as in study patients. A study concerned with the problem of 
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treatment abandonment in children from developing countries addresses this problem 
faced in many low-income countries.(7) However, there have also been other studies 
which failed to show a significant difference in outcome with regard to the treatment 
protocol.(116)  
4.2.8 Blood counts 
An aim of our study was to identify additional risk factors allowing for disease 
stratification on basis of simple tests such as differential blood count. Therefore, we 
performed a detailed analysis of individual blood parameters obtained in all children at 
diagnosis. 
Haemoglobin  
Results of the univariate analysis did not indicate a significant correlation neither 
between haemoglobin levels below age-related reference range and outcome nor 
between haemoglobin levels < 5g/dl and outcome at any of the given time points. The 
sole significant correlation was at 1 month between haemoglobin below reference 
range and outcome. However, we interpret this single significant value as irrelevant. 
Haemoglobin levels below range or severe anaemia have previously been shown to 
affect outcome and prognosis in certain haematological malignant diseases in 
children.(91,98) Severe anaemia has been reported to be a major contributor to 
mortality and death among children in Kenya.(35) Interestingly, Orem et al. described 
anaemia, which was not further defined, to be correlated to a decreased mortality in 
paediatric eBL.(98) However, they also mentioned the relationship between anaemia 
and facial tumours which are, as in our study, related to a better outcome.(98) This 
might have been a confounder. 
Leukocytes 
Neither leukopenia nor leucocytosis was significantly correlated to EFS at any time 
point. OR continuously indicated a trend towards leukopenia being an unfavourable 
characteristic for survival. Trends for leucocytosis pointed into the same direction but 
were not as distinct (ORs were closer to 1). 
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As mentioned above, literature on the subject of leukocytes in eBL is scarce, and no 
data have been reported on the impact of elevated or decreased levels of leukocytes 
on outcome. 
Neutrophils 
Similar to findings concerned with overall leukocytic counts, absolute neutropenia and 
neutrophilia did not have significant impact on survival. Moreover, ORs were rather 
unspecific and did not even reveal a trend. 
Neutropenia in the context of BL or NHL in general is often mentioned in relation to 
toxicity of chemotherapy.(58) To our knowledge, literature on neutropenia or 
neutrophilia at diagnosis of eBL or even sBL in children and its correlation to outcome, 
mortality or survival does not exist.  
Lymphocytes 
Alterations in absolute and relative lymphocytic counts as lymphopenia and 
lymphocytosis and its statistical analysis with concern to EFS showed a trend towards 
lymphopenia being an unfavourable factor for survival and lymphocytosis being a 
rather favourable condition. However, except for absolute lymphopenia at discharge 
(chi² 0.019) there was no significant correlation between absolute/relative 
lymphopenia respectively lymphocytosis (chi² 0.163-1.000).  
Certain researchers and clinicians have called for the implementation of lymphopenia 
as simple prognostic factor in lymphoma not differentiating between children and 
adults.(126) As mentioned for most of the other blood parameters, there is no work on 
either lymphopenia or lymphocytosis in eBL or other common NHL entities in 
childhood.  
Monocytes 
Children with absolute monocytosis tended to have an advantage with regard to  EFS. 
However there were not any significant results in Fisher’s exact test (chi² 0.107-0.890). 
In case of relative monocytosis there was neither advantage nor disadvantage for EFS 
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found as OR were not persistently above or below 1. Further, significance testing did 
not show any positive results (chi² 0.088-0.892).   
To our knowledge there is no literature on the subject of monocytosis at diagnosis in 
eBL or sBL.  
Eosinophils 
Eosinophils are the main focus of this work. Univariate analysis was performed 
correlating absolute eosinophilia to EFS at all 4 time points.  
Results indicate that eosinophilia may be favourable factor for an increased chance of 
EFS. Odds ratios revealed in statistical risk analysis hint for an almost 20-50% reduced 
risk of an event like death or relapse depending on the time point. As our study 
concept unfortunately did not allow overall calculation, results can only be interpreted 
for every single time point. However, at the end point of follow-up, OR was 0.532, 
indicating a 50% decreased risk of an event). Fisher’s exact testing revealed 
significance for these results at 1 month (chi² <0.04) and a slight significance at 12 
months (chi² 0.053). At the other 2 points in time, there was no significance shown 
(chi² dis: 0.644; 6: 0.205). Considering the results of the generalized linear model 
combining all time points they also illustrated positive coherence of eosinophilia and 
EFS (OR: 0.777 [0.521-1.158]). However, significance was not shown (chi² 0.215).  
Even tough, tumor-associated hypereosinophilia has been discussed to be a predictor 
of poor prognosis (109), Pulsoni et al. found that eosinophilia at diagnosis in 
adolescent to adult patients with acute myeloid leukaemia (AML) was a positive 
predictor for complete remission.(107) In contrast, Agarwal et al. did not find a 
significant correlation in childhood AML patients in India.(3) 
Reasons why our data could not reveal consistent significance relate to the small 
number of cases with eosinophilia and the decreasing number of cases throughout the 
study time. Another reason could be the cut-offs set. It would certainly be 
advantageous to base the cut-offs on local reference values, however, such values do 
not exist.  
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4.3 Confounding parameters affecting eosinophilia  
We identified stage and localisation as parameters significantly affecting outcome in 
eBL patients in Malawi. Moreover, we obtained first evidence that eosinophilia at 
diagnosis may also be associated with outcome. To strengthen the significance of this 
finding, we had to rule out confounding effects of other parameters on eosinophilia. In 
summary, we could show a significant correlation between eosinophilia and 
localisation, stage, parasitic infection of the urinary tract respectively CNS 
manifestation. As localisation and stage are also the main parameters affecting 
outcome, confounding effects must be expected.   
4.3.1 Stage 
Limited disease (I, II) has a 2.5 times raised chance to present with eosinophilia than 
extensive disease (III, IV) (chi² 0.000). Also stage I-III had a 2 times increased chance for 
eosinophilia than stage IV patients (chi² 0.017). 
Likewise, due to lack of studies, no other studies were available for comparison.  
4.3.2 Localisation 
Additionally, our statistical analysis revealed a significant correlation of eosinophilia to 
localisation. Patients with facial tumour had 2 times increased odds to present with 
eosinophilia in comparison to patients with abdominal tumour (chi² 0.003). Further, 
patients with no abdominal involvement at all had a 2 times increased chance to have 
eosinophilia (chi² 0.001). Since literature lacks information on eosinophilia in eBL, we 
were not able to compare our findings to others. Besides, we did not find any specific 
work on eosinophilia in other NHL entities.  
4.3.3 Parasitic infections 
Any parasitic infection of the urinary tract (mainly Schistosomiasis) was related to 3.5 
times increased chance on eosinophilia at presentation compared to patients not 
suffering from it (chi² 0.000). Also in parasitic infections of the bowels at admission, 
chances to present with eosinophilia were 2 times increased compared to patients 
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without eosinophilia. However, Fisher’s exact testing did not reveal significance (chi² 
>0.100). In contrast, the odds for eosinophilia were about 0.8 times decreased in case 
of malaria though results were not significant (chi² 0.706).  
Eosinophilia is commonly described in patients with Schistosomiasis (120) which is the 
main parasitic infection of the urinary tract in Malawi.(63) Therefore, our findings 
reflect common characteristics of our patient cohort. Besides this, other helminthic 
infections can also cause eosinophilia, e. g. Strongyloides stercoralis 
(58,75,78,73).(80,106,118,120) These are mainly tissue invading parasites. Other 
parasitic infections affecting the bowels, as Giardia lamblia or Enterobius vermicularis, 
do usually not provoke eosinophilia as they solely affect the intraluminal part of the 
gastrointestinal tract or stay within the tissue.(66)  This could explain why we did not 
find significance for eosinophilia and parasites in stools. Concerning malaria, 
eosinophilia has been described to be an important characteristic in cerebral malaria 
(67) though another investigations on malaria in general did not reveal an association 
to eosinophilia.(77) For this reason, it is not surprising that eosinophilia did not 
correlate with malaria in our patient cohort.  
4.3.4 CNS manifestation 
CNS involvement did reduce the odds to present at the same time with eosinophilia for 
almost 3 times (chi² 0.043). Considering that CNS involvement is related to more 
progressed disease (87) which in turn is related to a worse outcome (22) and to 
eosinophilia which is hypothesised in this work to be a positive prognostic factor for 
EFS, CNS might be a confounding parameter. 
To our knowledge, there is no data about eosinophilia in CNS involvement in eBL or 
sBL. 
4.4 Independent prognostic variables in paediatric eBL in Malawi 
In order to identify factors which independently influence EFS in eBL, we performed a 
multivariate analysis with a generalized linear model. It detected stage to be the major 
effector for EFS and sole significant parameter among children with eBL treated at 
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QECH affecting survival. Presenting with extensive disease (stage III and IV) at 
admission implies a 1.58 times increased risk for an event (Wald chi² 0.019). Besides 
stage, no other parameter significantly influencing EFS was identified.  
This result is confirmatory of previous results leading to current risk stratification in BL. 
Similar results revealed by various authors and study groups strengthen and support 
this finding.(8,22,23,93,96,98)  
Technically, these results are reassuring for the reliability of our retrospectively 
assessed data.  
Even though our hypothesis that eosinophilia has a significant impact on the risk of 
events as death and relapse in eBL was not confirmed, we showed by univariate 
analysis that eosinophilia at diagnosis decreases the risk of an event by about one 
quarter in comparison to patients without eosinophilia. The lack of significance in 
multivariate analysis may be due to the small number of cases with eosinophilia. Other 
reasons could be the choice of defining values for eosinophilia. As discussed the 
definition of eosinophilia is not explicit. Various literature sources contain different 
values and cut-offs. Other reasons could be the lack of quality in assessing eosinophilic 
levels, staging and diagnosis of eBL in general under low-resource conditions as we 
find them in Malawi. It might also not be eosinophilia affecting survival positively but 
eosinopenia affecting survival negatively.  
However, our observations provide a basis for further research on this subject as it 
seems to bear potential which needs to be assessed in a more elaborate way. 
Specifically, a prospective study could clarify the role of eosinophilia as prognostic 
factor for survival in paediatric eBL. As we recommend further efforts on this subject, 
we want to recall once again the urgent need for advanced risk stratification tools in 
these low-income countries.  
As mentioned in the introduction, eosinophils have been found to have cytotoxic 
effects on tumour cells.(43,54,111) Direct as well as indirect mechanisms of cytotoxic 
effects on tumour cells have been suggested.(90,111) Furthermore, apoptotic 
induction of tumour cells by eosinophils has been reported.(68) This provides 
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important evidence that moderately elevated eosinophilic counts could be a positive 
prognostic factor for survival. However, it should also be considered that extremely 
elevated blood eosinophils called hypereosinophilic syndrome can cause tremendous 
organ damage and are not considered to be a characteristic favouring a positive 
survival. Another explanatory model could be an immunoregulatory role of eosinophils 
considering their promoting effects on T-lymphocytes.(72) Even though mechanisms 
are not completely understood and findings are conflictive, a potential role in tumour 
immunity has been attributed to T-lymphocytes.(56,62) However, as the mechanisms 
of the human immune system are extremely complex, these thoughts remain 
speculative. Extensive research efforts to understand and reveal these mechanisms 
have to be continued in order to promote understanding and to facilitate therapy 
improvements for patients.  
5 SUMMARY 
Even though infectious diseases still make up the largest burden of disease among 
children in developing countries, malignancies become more relevant in these areas, 
too. For instance, endemic Burkitt lymphoma is one of the most common paediatric 
cancer entities in Malawi and represents a serious burden. Since resources are scarce 
in these countries, there is an urgent need for optimized therapies. Advanced risk 
stratification could contribute to a more efficient application of available resources. 
Derived from clinical experience, eosinophilia might play a role in risk assessment for 
children with endemic Burkitt lymphoma.  
In this retrospective study, 479 cases of paediatric endemic Burkitt lymphoma in 
Malawi between 1997 and 2009 were included. Information on various parameters 
such as tumour stage and eosinophilic counts was drawn from patients’ files. Crucial 
factors for survival were identified through extensive literature research, respectively 
univariate analysis and included in an interval censored general linear model. Through 
this statistical tool, the interrelations between characteristics could be assessed and 
independently influencing factors for survival could eventually be identified. 
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The median age was 7.0 years with a male:female ratio of 1.8:1. Sixty-nine patients 
(14.4%) had stage I disease, 107 (22.3%) stage II, 224 (46.8%) stage III and 73 (15.2%) 
stage IV. The median eosinophilic count was 0.10 x 10³/µl (range: 0:00 to 9:50 x 10³/ 
µl). Most patients (232, 48,4%) presented with exclusive facial localisation of the 
tumor whereas less patients had sole abdominal manifestation or a combination of 
both. 122 children (25.5%) presented with eosinophilia while the largest part of the 
study cohort (185 patients, 38,6%) presented with eosinopenia. Within 12 months 174 
patients (36.3%) suffered recurrence or death, 77 (16.1%) remained free of tumor. The 
largest part of study population did not show up or were not traceable for final follow-
up examinations. The multivariate analysis showed that patients with stage III, IV, had 
a significantly increased risk of an event (chi² 0.019, exp(B) 1.579 [1.082-2.359]), 
whereas patients with eosinophilia showed a non-significant decreased risk of an event 
(chi² 0.215, exp (B) 0.777 [0.521-1.158]). Stage was the sole parameter which was 
shown to have a significant impact on survival in multivariate analysis. 
Eosinophilia was not identified as an independently influencing characteristic 
concerning survival. Even though the hypothesis could not be proved, important and 
inspiring aspects for risk stratification in paediatric endemic Burkitt lymphoma could 
be gained. It might not be eosinophilia which is favouring survival but eosinopenia 
which is affecting the chance on survival negatively.  
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6 INDEX 
6.1 Abbreviations & Units 
µl Microliter 
AIDS Acquired immunodeficiency syndrome 
ALL Acute lymphoid leukaemia 
AML Acute myeloid leukaemia 
ARA-C Cytarabine 
BL Burkitt lymphoma 
BM Bone marrow 
CNS Central nervous system 
COMP Vincristine, cyclophosphamide, methotrexate i.v., prednisone, 
methotrexate intrathecal + hydrocortison 
COP Vincristine, cyclophosphamide, prednisone  
CPM Cyclophosphamide 
CSF Cerebro-spinal fluid 
CYM Cytarabine intrathecal, vincristine, methotrexate i.v., 
methotrexate intrathecal + hydrocortisone  
eBL Endemic Burkitt lymphoma 
EBV Epstein-Barr Virus 
EFS Event-free survival 
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HC Hydrocortison 
HIV Human immunodeficiency virus 
LDH Lactate dehydrogenase 
NHL Non-Hodgkin lymphoma 
QECH Queen Elizabeth Central Hospital 
sBL Sporadic Burkitt lymphoma  
UNICEF United Nations International Children’s Emergency Found 
VCT Voluntary counselling and testing 
VINC Vincristine 
WBC White blood cells 
WHO World Health Organization  
6.2 Tables 
 
Table 2.1 St. Jude (Murphy’s) Classification for Childhood Non-Hodgkin 
lymphoma       
8 
 
Table 2.2 Reference values Differential Blood 10 
Table 3.2 Chemotherapy Schedule 1997-1999 22 
Table 3.3 Generalized linear model Parameter estimates 46 
Table 4.1 Overview - Survival eBL studies and publications (arranged by 
publishing year) 
55 
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6.3 Diagrams 
 
Diagram 3.1 Age distribution (frequencies) 14 
Diagram 3.2 Stage distribution (percent)  15 
Diagram 3.3 Tumour localisation at presentation (percent) 16 
Diagram 3.4 HIV status (percent) 17 
Diagram 3.5 Haemoglobin distribution (histogram) 18 
Diagram 3.6 White blood cells (histogram) 19 
Diagram 3.7 Absolute eosinophils (histogram) 20 
Diagram 3.8 Classification Absolute Eosinophils (percent) 21 
Diagram 3.9 EFS at discharge (percent) 24 
Diagram 3.10 EFS at 1 month 25 
Diagram 3.11 EFS at 6 months  25 
Diagram 3.12 EFS at 12 months  26 
Diagram 3.13 EFS at discharge by stage                   28 
Diagram 3.14 EFS at 1 month by stage 28 
Diagram 3.15 EFS at 6 months by stage 29 
Diagram 3.16 EFS at 12 months by stage 29 
Diagram 3.17 EFS at discharge by localisation  31 
Diagram 3.18 EFS at 1 month by localisation 32 
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Diagram 3.19 EFS at 6 months by localisation  32 
Diagram 3.20 EFS at 12 months by localisation 33 
Diagram 3.21 EFS at discharge by eosinophilia  40 
Diagram 3.22 EFS at 1 month by eosinophilia 40 
Diagram 3.23 EFS at 6 months by eosinophilia 41 
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